{"text": "The present study confirms these observations and provides evidence of the equal efficacy and in vivo potency of intravenous rapid - acting insulin analogs and regular insulin in patients with severe hyperglycemia and ketoacidosis .", "label": "", "metadata": {}, "score": "40.37343"}
{"text": "Addressing the problem of psychological insulin resist- ance in type 2 diabetes .U.K. Prospective Diabetes Study 16 .Overview of 6 years therapy of type II diabetes : a progressive disease .", "label": "", "metadata": {}, "score": "43.669914"}
{"text": "Ohkubo Y , Kishikawa H , Araki E , Isami S , Motoyoshi S , Kojima Y , Furuyoshi N , Shichiri M : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non - insulin - dependent diabetes mellitus : a randomized prospective 6-year study .", "label": "", "metadata": {}, "score": "43.82163"}
{"text": "One important reason for this is failure to appropriately initi- ate insulin therapy in a timely manner [ 8].The United Kingdom Prospective Diabetes Study demon- strated the progressive decline in p - cell function that occurs over time in type 2 diabetes and the eventual need for insulin therapy in most patients [ 9,10].", "label": "", "metadata": {}, "score": "44.701866"}
{"text": ": A comparison of the steady - state pharmacokinetics and pharmacodynamics of a novel rapid - acting insulin analog , insulin glulisine , and regular human insulin in healthy volunteers using the euglycemic clamp technique .", "label": "", "metadata": {}, "score": "44.763855"}
{"text": "Once insulin has success- fully reversed the glucose toxicity , many of these newly diagnosed patients can then be controlled on OADs [ 2,12].", "label": "", "metadata": {}, "score": "44.910427"}
{"text": "Background .The aim of this study is to compare the efficacy of intensification of insulin treatment with insulin glargine and biphasic human insulin in patients with type 2 diabetes on concomitant therapy with oral antidiabetic drugs ( OAD ) in daily clinical practice .", "label": "", "metadata": {}, "score": "45.141922"}
{"text": "Background .The aim of this study is to compare the efficacy of intensification of insulin treatment with insulin glargine and biphasic human insulin in patients with type 2 diabetes on concomitant therapy with oral antidiabetic drugs ( OAD ) in daily clinical practice .", "label": "", "metadata": {}, "score": "45.141922"}
{"text": "Intensification of insulin therapy in patients with type 2 diabetes : a retrospective , non- interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice .", "label": "", "metadata": {}, "score": "46.10746"}
{"text": "[Medline ] [ CrossRef ] 8 .Urakami T , Morimoto S , Nitadori Y , Harada K , Owada M , Kitagawa T. Glucose screening program at schools in Japan to detect children with diabetes and its outcome - Incidence and clinical characteristics of childhood type 2 diabetes in Japan .", "label": "", "metadata": {}, "score": "46.501938"}
{"text": "We conducted a nonsystematic review in PubMed and identified the most relevant and recently published articles that compared the use of premixed insulin versus basal insulin analogues used alone or in combination with rapid - acting insulin analogues before meals in patients with T2DM .", "label": "", "metadata": {}, "score": "46.525063"}
{"text": "It is also important that clinicians discuss and come to an agreement with patients on specific treatment goals for basal - prandial insulin therapy [ 13].", "label": "", "metadata": {}, "score": "47.28262"}
{"text": "This is the first prospective randomized trial to compare the use of insulin analogs and human insulins both during acute intravenous treatment and during the transition to subcutaneous insulin in patients with DKA .", "label": "", "metadata": {}, "score": "47.43963"}
{"text": "Introduction .Insulin can be administered in addition to oral hypoglycaemic therapy and in different therapeutic schemes which can be prospectively modified based on close glycosylated haemoglobin A1c ( HbA1c ) and blood glucose ( BG ) monitoring [ 3 ] .", "label": "", "metadata": {}, "score": "47.74027"}
{"text": "Introduction .Insulin can be administered in addition to oral hypoglycaemic therapy and in different therapeutic schemes which can be prospectively modified based on close glycosylated haemoglobin A1c ( HbA1c ) and blood glucose ( BG ) monitoring [ 3 ] .", "label": "", "metadata": {}, "score": "47.74027"}
{"text": "We analysed 536 patient cases from general practice ( 63 % ) and endocrinological outpatient clinics ( 37 % ) .Both bivariate analyses and multivariate regression analyses were applied to examine whether there were differences in the daily doses of insulin detemir and insulin glargine .", "label": "", "metadata": {}, "score": "47.975372"}
{"text": "The availability of newer rapid - acting and long - acting insulin analogs that closely mimic normal endogenous prandial and basal insulin secretion provides an unprecedented opportunity for more physiologic insulin replacement .", "label": "", "metadata": {}, "score": "48.117973"}
{"text": "Thus , real - world studies such as the present study play an important role in terms of providing evidence of actual insulin utilisation .A major strength of this study is that data was collected directly from the treating physician giving precise information on prescribed insulin dose in units per day .", "label": "", "metadata": {}, "score": "48.304176"}
{"text": "[ 22 ] reviewed 22 trials that randomized 4,379 insulin - na\u00efve patients .In our study the addition of fast acting insulin when necessary to basal insulin glargine resulted in greater HbA1c and fasting BG reduction , which almost reached the suggested by the ADA / EASD guidelines levels [ 1 , 2 , 15 ] .", "label": "", "metadata": {}, "score": "48.476295"}
{"text": "[ 22 ] reviewed 22 trials that randomized 4,379 insulin - na\u00efve patients .In our study the addition of fast acting insulin when necessary to basal insulin glargine resulted in greater HbA1c and fasting BG reduction , which almost reached the suggested by the ADA / EASD guidelines levels [ 1 , 2 , 15 ] .", "label": "", "metadata": {}, "score": "48.476295"}
{"text": "Well controlled studies on the comparative evaluation of the effectiveness and safety of the different insulin schemes are limited .Raskin et al .[19 ] in a 28-week parallel group randomized study involving 233 insulin - na\u00efve patients with T2DM on treatment with metformin , found that biphasic insulin twice daily was more effective in lowering HbA1c compared to treatment with once daily insulin glargine .", "label": "", "metadata": {}, "score": "48.858677"}
{"text": "Well controlled studies on the comparative evaluation of the effectiveness and safety of the different insulin schemes are limited .Raskin et al .[19 ] in a 28-week parallel group randomized study involving 233 insulin - na\u00efve patients with T2DM on treatment with metformin , found that biphasic insulin twice daily was more effective in lowering HbA1c compared to treatment with once daily insulin glargine .", "label": "", "metadata": {}, "score": "48.858677"}
{"text": "PubMed View Article .McAdam - Marx C , Yu J , Bouchard J , Aagren M , Brixner DI : Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin .", "label": "", "metadata": {}, "score": "49.028503"}
{"text": "Clinical and laboratory examinations .CONCLUSIONS- .This is one of the few randomized controlled trials to evaluate basal - bolus analog insulin therapy in obese patients with type 2 diabetes and one of the first studies to evaluate the use of carbohydrate counting in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "49.299255"}
{"text": "This higher premixed insulin can also be an initial choice of treatment for patients who may need higher daily doses of rapid insulin or those who eat meals with a high carbohydrate content [ 18 , 53 ] .", "label": "", "metadata": {}, "score": "49.381485"}
{"text": "After transition to subcutaneous insulin therapy , cross - sectional analyses based on two - sample Wilcoxon tests showed that there were no significant differences in the mean daily glucose concentration between treatment groups .", "label": "", "metadata": {}, "score": "49.418182"}
{"text": "However , we stress the fact that treatment needs to be individualized based on the results of a recent comparison of BIAsp 30 with insulin glargine in patients with T2DM who were not achieving glycemic targets on basal insulin or AHAs [ 57 ] .", "label": "", "metadata": {}, "score": "49.580685"}
{"text": "[Medline ] [ CrossRef ] 17 .Seino Y , Rasmussen MF , Zdravkovic M , Kaku K. Dose - dependent improvement in glycemia with once - daily liraglutide without hypoglycemia or weight gain : A double - blind , randomized , controlled trial in Japanese patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "49.64329"}
{"text": "If the treatment goals of these diet and exercise regimens are not met , pharmacologic therapies using oral hypoglycemic drugs ( OHDs ) and finally insulin therapy are introduced for children with T2DM ( 4 , 5 ) .", "label": "", "metadata": {}, "score": "49.73876"}
{"text": "A total of 142 patients who had switched treatment from biphasic human insulin to insulin glargine daily were included in the active group and compared to 159 patients who continued treatment with biphasic human insulin bd and were included in the control group .", "label": "", "metadata": {}, "score": "49.897926"}
{"text": "A total of 142 patients who had switched treatment from biphasic human insulin to insulin glargine daily were included in the active group and compared to 159 patients who continued treatment with biphasic human insulin bd and were included in the control group .", "label": "", "metadata": {}, "score": "49.897926"}
{"text": "In the present study , we showed that patients with type 2 diabetes using fasting and mealtime SMBG testing alone to monitor and adjust their rapid - acting and long - acting insulin analogs achieved excellent glucose control as measured by A1C , with minimal severe hypoglycemia .", "label": "", "metadata": {}, "score": "49.9745"}
{"text": "2008 , 31 ( suppl.2 ) : S131-S135 .View Article PubMed .Janka HU , Plewe G , Riddle MC , Kliebe - Frisch C , Schweitzer MA , Yki - J\u00e4rvinen H : Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes .", "label": "", "metadata": {}, "score": "50.706833"}
{"text": "2008 , 31 ( suppl.2 ) : S131-S135 .View Article PubMed .Janka HU , Plewe G , Riddle MC , Kliebe - Frisch C , Schweitzer MA , Yki - J\u00e4rvinen H : Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes .", "label": "", "metadata": {}, "score": "50.706833"}
{"text": "Therefore , our data suggest that addition of basal insulin to OAD is an effective approach for the management of hyperglycaemia in T2DM and intensification of insulin therapy with the addition of fast - acting pre - meal insulin may be necessary to achieve glucose targets .", "label": "", "metadata": {}, "score": "50.779087"}
{"text": "Therefore , our data suggest that addition of basal insulin to OAD is an effective approach for the management of hyperglycaemia in T2DM and intensification of insulin therapy with the addition of fast - acting pre - meal insulin may be necessary to achieve glucose targets .", "label": "", "metadata": {}, "score": "50.779087"}
{"text": "Although primary care clinicians may con- sider referral of patients considered for basal - prandial insulin regimens , this strategy can be appropriately imple- mented within most primary care offices .", "label": "", "metadata": {}, "score": "51.000446"}
{"text": "Urakami et al .4 insulin alone or in combination with additional medications followed by SUs ; i.e. , 11 patients received insulin alone or with an additional OHD such as metformin or glimepiride , and 9 were treated with glimepiride alone or in combination with another OHD .", "label": "", "metadata": {}, "score": "51.01596"}
{"text": "Available Insulin and Other Injectable Preparations Various insulins with different time - action profiles are currently available and can be used as part of a basal - pran- . dial insulin regimen ( Table 4 ) .", "label": "", "metadata": {}, "score": "51.824135"}
{"text": "This article must therefore be hereby marked \" advertisement \" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact .: Pharmacokinetics of 125 I - labeled insulin glargine ( HOE 901 ) in healthy men : comparison with NPH insulin and the influence of different subcutaneous injection sites .", "label": "", "metadata": {}, "score": "51.905647"}
{"text": "was?used?most?frequently , ? being the most commonly prescribed drug at that time for Japanese children with T2DM , followed by insulin , metformin , SU , nateglinide , and a combination?of?\u03b1 - GI?and?metformin .", "label": "", "metadata": {}, "score": "51.938217"}
{"text": "This study assessed the efficacy and safety of once - daily insulin initiation using insulin detemir ( detemir ) or insulin glargine ( glargine ) added to existing metformin in type 2 diabetes ( T2D ) ... .", "label": "", "metadata": {}, "score": "51.9683"}
{"text": "Many patients who were initially treated with a single drug eventually required insulin alone or in combination with an additional medication , suggesting that their glycemic control had deteriorated during the course of treatment .", "label": "", "metadata": {}, "score": "52.022285"}
{"text": "In summary , our study indicates that intravenous treatments with regular insulin and glulisine insulin are equally effective with no differences in the mean duration of treatment or in the amount of insulin infusion until resolution of DKA .", "label": "", "metadata": {}, "score": "52.10534"}
{"text": "Their rapid absorption due to the rapid component and the more pronounced onset of insulin action means that these analogues can be dosed immediately before or following a meal [ 26 , 43 , 44 ] .", "label": "", "metadata": {}, "score": "52.31952"}
{"text": "The total daily dose of insulin was lower , and there was a trend toward less weight gain in carb count group patients .Severe hypoglycemia rates were low and equal in the two groups .", "label": "", "metadata": {}, "score": "52.328438"}
{"text": "Neither large , randomized studies of intensive basal - bolus analog insulin therapy in patients with type 2 diabetes nor studies evaluating the efficacy of carbohydrate counting in type 2 diabetes have been conducted .", "label": "", "metadata": {}, "score": "52.362076"}
{"text": "A reduction in insulin dose requirements by increasing the patient 's sensitivity to insulin through diet and exercise can be effective .Administration of insulin in patterns that simulate physiologic insulin secretion can also help control weight gain and can be achieved with premixed insulin analogues , e.g. , BIAsp 30 and LM .", "label": "", "metadata": {}, "score": "52.661575"}
{"text": "Our study and these previous reports indicate that treatments with intravenous glulisine and regular insulin are equally safe and efficacious in the acute management of patients with DKA .", "label": "", "metadata": {}, "score": "52.797318"}
{"text": "It may be that our simple algorithm group patients either consumed fairly consistent amounts of carbohydrates , thus minimizing needed changes in insulin dosing , or learned to modify their carbohydrate intake based on SMBG measurements .", "label": "", "metadata": {}, "score": "52.883743"}
{"text": "The aim of this study was to compare real - life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients when administered once daily .", "label": "", "metadata": {}, "score": "52.974182"}
{"text": "Raskin P , Klaff L , Bergenstal R , Halle JP , Donley D , Mecca T : A 16-week comparison of the novel insulin analog insulin glargine ( HOE 901 ) and NPH human insulin used with insulin lispro in patients with type 1 diabetes .", "label": "", "metadata": {}, "score": "53.041702"}
{"text": "Once - daily initiation of basal insulin as add - on to metformin : a 26-week , randomized , treat - to - target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "53.239845"}
{"text": "Publications 20 .Why and how to use insulin therapy earlier in the management of type 2 diabetes .Luigi Meneghini Eleanor and Joseph Kosow Diabetes Treatment Center , Diabetes Research Institute , Miami , FL 33136 , USA South Med J 100:164 - 74 .", "label": "", "metadata": {}, "score": "53.5178"}
{"text": "However , insulin .This review provides practical recommenda- tions for initiating basal and basal - prandial insulin ther- apy in type 2 diabetes , with a focus on insulin analogs .", "label": "", "metadata": {}, "score": "53.701576"}
{"text": "Use of rapid- acting insulin analogs has been associated with improved PPG control and a reduced incidence of severe and noctur- nal hypoglycemia , compared with regular human insulin [ 14].", "label": "", "metadata": {}, "score": "54.01919"}
{"text": "In addition , 9 patients were treated with basal insulin supported with oral hypoglycemic drugs ( OHDs ) or biphasic premix insulin .On the other hand , the 23 nonobese patients were frequently treated with insulin alone or in combination with an additional medication followed by SUs .", "label": "", "metadata": {}, "score": "54.321438"}
{"text": "It also aims to provide practical aspects of insulin treatment that can be used to encourage and motivate patients to comply with treatment and ultimately attain desirable glycemic control .", "label": "", "metadata": {}, "score": "54.326927"}
{"text": "This observation also indicates that endogenous insulin secretion is reduced earlier in nonobese than in obese children with T2DM .Drugs targeting the incretin system , i.e. , DPP-4 inhibitors and GLP-1 receptor agonists , have recently been introduced ( 15 - 17 ) .", "label": "", "metadata": {}, "score": "54.331913"}
{"text": "Thus it is important to balance the potential benefits of intensive control with the risk of such intensive targets .Weight gain , a main limitation of insulin treatment , can significantly affect patient treatment compliance .", "label": "", "metadata": {}, "score": "54.363495"}
{"text": "Discussion Because the pathophysiology of T2DM in children appears to be similar to that in adults , it is reasonable to assume that OHDs as well as insulin would be effective in children with T2DM who fail to improve glycemic control through diet and exercise regimens .", "label": "", "metadata": {}, "score": "54.375496"}
{"text": "Subjects receiving insulin therapy before admission received the same outpatient insulin amount , with the TDD switched to glargine and glulisine or to NPH and regular insulin on a unit - for - unit basis .", "label": "", "metadata": {}, "score": "54.40049"}
{"text": "Clin Ther .10.1016/j.clinthera.2007.05.017 .View Article PubMed .Heise T , Heinemann L , Hovelmann U , Brauns B , Nosek L , Haahr HL , Olsen KJ : Biphasic insulin aspart 30/70 : pharmacokinetics and pharmacodynamics compared with once - daily biphasic human insulin and Basal - bolus therapy .", "label": "", "metadata": {}, "score": "54.415268"}
{"text": "To compare the efficacy and safety of 2 intensification strategies for stepwise addition of prandial insulin aspart in patients with type 2 diabetes mellitus treated with insulin detemir ... .", "label": "", "metadata": {}, "score": "54.626404"}
{"text": "Due to its pharmacodynamic profile , insulin glargine substitutes basal insulin secretion effectively controlling morning glycaemia , whereas fast acting insulin reduces postprandial hyperglycaemia .The strength of this study is that it examined in everyday clinical practice with no intervention at all and with adequate power the effectiveness of intensification of treatment with insulin based on two insulin regimens ( basal insulin glargine vs. biphasic human insulin ) on glycemic control .", "label": "", "metadata": {}, "score": "54.77307"}
{"text": "Due to its pharmacodynamic profile , insulin glargine substitutes basal insulin secretion effectively controlling morning glycaemia , whereas fast acting insulin reduces postprandial hyperglycaemia .The strength of this study is that it examined in everyday clinical practice with no intervention at all and with adequate power the effectiveness of intensification of treatment with insulin based on two insulin regimens ( basal insulin glargine vs. biphasic human insulin ) on glycemic control .", "label": "", "metadata": {}, "score": "54.77307"}
{"text": "View Article .Mudaliar S , Edelman SV : Insulin therapy in type 2 diabetes .Endocrinol Metab Clin North Am 2001 , 30 ( 4 ) : 935 - 982 .", "label": "", "metadata": {}, "score": "55.25188"}
{"text": "For patients whose main meal is dinner , a premixed insulin analogue can be initiated with a single dose of 10 U or 0.1 U / kg before dinner followed by an evaluation of the effect on BG before breakfast .", "label": "", "metadata": {}, "score": "55.256996"}
{"text": "A rapid - acting insulin may need to be added to 1 or more meals ( eg , at lunchtime since the morning NPH insulin has been eliminated - this can be determined by monitor- ing postlunch or predinner glucose levels ) .", "label": "", "metadata": {}, "score": "55.42653"}
{"text": "According to major studies performed in patients with T2DM using insulin premixtures [ 20 , 53 , 54 , 58 - 62 ] , the titration schedule should take into account the number of injections that the patient is receiving .", "label": "", "metadata": {}, "score": "55.47942"}
{"text": "Once the physician has opted for a premixed insulin , such as LM25 or BIAsp 30 , insulin can be administered initially at a dose of 10 U or 0.1 U / kg before breakfast .", "label": "", "metadata": {}, "score": "55.48793"}
{"text": "PubMed View Article .Heise T , Pieber TR : Towards peakless , reproducible and long - acting insulins .An assessment of the basal analogues based on isoglycaemic clamp studies .", "label": "", "metadata": {}, "score": "55.68657"}
{"text": "PubMed View Article .Borah BJ , Darkow T , Bouchard J , Aagren M , Forma F , Alemayehu B : A comparison of insulin use , glycemic control , and health care costs with insulin detemir and insulin glargine in insulin - naive patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "55.872795"}
{"text": "In the active group , more patients received rapid - acting pre - meal insulin and used insulin secretagogues drugs .Conclusions .Glargine alone or in combination with fast acting insulin is more effective in reducing glycaemia than biphasic human insulin alone or in combination with fast acting insulin in patients with type 2 diabetes without increase in hypoglycaemic episodes or body weight .", "label": "", "metadata": {}, "score": "55.976307"}
{"text": "In the active group , more patients received rapid - acting pre - meal insulin and used insulin secretagogues drugs .Conclusions .Glargine alone or in combination with fast acting insulin is more effective in reducing glycaemia than biphasic human insulin alone or in combination with fast acting insulin in patients with type 2 diabetes without increase in hypoglycaemic episodes or body weight .", "label": "", "metadata": {}, "score": "55.976307"}
{"text": "For example , if blood glucose levels are high before lunch , add 5 - 10 U of rapid - acting insulin at breakfast , with continued titration according to the sched- ule shown in Table 6 .", "label": "", "metadata": {}, "score": "56.012672"}
{"text": "Riddle MC , Rosenstock J , Gerich J , on behalf of the Insulin Glargine 4002 Study Investigators : The Treat - to - Target Trial : rand- omized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients .", "label": "", "metadata": {}, "score": "56.099228"}
{"text": "However , their results were modified three years after randomization and patients who added a basal or fast acting insulin - based regimen had better glycaemic control than patients who added biphasic insulin [ 20 ] .", "label": "", "metadata": {}, "score": "56.248516"}
{"text": "However , their results were modified three years after randomization and patients who added a basal or fast acting insulin - based regimen had better glycaemic control than patients who added biphasic insulin [ 20 ] .", "label": "", "metadata": {}, "score": "56.248516"}
{"text": "The combination of oral hypoglycaemic agents and insulin administration has become a favourable type of treatment achieving effective control with lower insulin dosage in T2DM .", "label": "", "metadata": {}, "score": "56.260506"}
{"text": "The combination of oral hypoglycaemic agents and insulin administration has become a favourable type of treatment achieving effective control with lower insulin dosage in T2DM .", "label": "", "metadata": {}, "score": "56.260506"}
{"text": "Diabetes .2006 , 55 ( Suppl 1 ) : 554-P- .Raskin P , Allen E , Hollander P , Lewin A , Gabbay RA , Hu P , Bode B , Garber A , INITIATE Study Group : Initiating insulin therapy in type 2 Diabetes : a comparison of biphasic and basal insulin analogs .", "label": "", "metadata": {}, "score": "56.348793"}
{"text": "Insulin may be given in different therapeutic schemes either alone or in combination with OAD depending on the severity of the disease and appointed glycaemic targets .", "label": "", "metadata": {}, "score": "56.358627"}
{"text": "Insulin may be given in different therapeutic schemes either alone or in combination with OAD depending on the severity of the disease and appointed glycaemic targets .", "label": "", "metadata": {}, "score": "56.358627"}
{"text": "J Clin Endocrinol Metab 2009 ; 94 : 564 - 569 Abstract .Background .The uncertainties regarding dose similarities between basal long - acting insulin analogues remain .", "label": "", "metadata": {}, "score": "56.393204"}
{"text": "Recent data suggest that less aggressive FPG goals may also be effective as long as close monitoring of glucose and active dose titration of insulin are implemented [ 38].", "label": "", "metadata": {}, "score": "56.46708"}
{"text": "PubMed View Article .Monami M , Marchionni N , Mannucci E : Long - acting insulin analogues versus NPH human insulin in type 2 diabetes : a meta - analysis .", "label": "", "metadata": {}, "score": "56.54233"}
{"text": "PubMed View Article .Philis - Tsimikas A , Charpentier G , Clauson P , Ravn GM , Roberts VL , Thorsteinsson B : Comparison of once - daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes .", "label": "", "metadata": {}, "score": "56.60004"}
{"text": "Kaufman FR , Halvorson M , Carpenter S : Use of a plastic insulin dosage guide to correct blood glucose levels out of the target range and for carbohydrate counting in subjects with type 1 diabetes .", "label": "", "metadata": {}, "score": "56.738262"}
{"text": "Monthly number ( mean \u00b1 SD ) of hypoglycemic episodes and number ( % ) of patients with hypoglycaemia per treatment group during the reporting period of treatment with biphasic insulin or insulin glargine .", "label": "", "metadata": {}, "score": "56.815907"}
{"text": "Monthly number ( mean \u00b1 SD ) of hypoglycemic episodes and number ( % ) of patients with hypoglycaemia per treatment group during the reporting period of treatment with biphasic insulin or insulin glargine .", "label": "", "metadata": {}, "score": "56.815907"}
{"text": "Based on home glucose monitoring data , patients may be converted from split - mixed or premixed insulin regimens to basal - prandial regimens with similar ease .", "label": "", "metadata": {}, "score": "56.925987"}
{"text": "Practical Recommendations for Patient Selection A combination of basal insulin with OADs or basal - pran- dial insulin therapy are both appropriate treatment options for patients with type 2 diabetes who are : .", "label": "", "metadata": {}, "score": "56.975594"}
{"text": "Premixed insulin analogues can be used in insulin - na\u00efve patients , in patients already on basal insulin therapy , and those using basal - bolus therapy who are noncompliant with blood glucose self - monitoring and titration of multiple insulin doses .", "label": "", "metadata": {}, "score": "57.018135"}
{"text": "In both treatment groups , fast acting insulin was added if needed .Research design and methods .A retrospective parallel two - arm study was designed to include 332 patients with T2DM , equally distributed in two treatment groups .", "label": "", "metadata": {}, "score": "57.09831"}
{"text": "In both treatment groups , fast acting insulin was added if needed .Research design and methods .A retrospective parallel two - arm study was designed to include 332 patients with T2DM , equally distributed in two treatment groups .", "label": "", "metadata": {}, "score": "57.09831"}
{"text": "Typically , if significant glycemic benefit with the OAD was achieved prior to starting insulin therapy , the drug may be continued .In some patients , it may be appropriate also to reduce basal insulin doses after start- ing prandial insulin with continued monitoring of FPG levels .", "label": "", "metadata": {}, "score": "57.197544"}
{"text": "10.1016/j.jdiacomp.2005.09.004 .View Article PubMed .Jacober SJ , Scism - Bacon JL , Zagar AJ : A comparison of intensive mixture therapy with basal insulin therapy in insulin - naive patients with type 2 diabetes receiving oral antidiabetes agents .", "label": "", "metadata": {}, "score": "57.24945"}
{"text": "In the present study , we found that nonobese patients tended to require pharmacologic therapy , in particular insulin , at an earlier stage of diabetes as compared with obese patients .", "label": "", "metadata": {}, "score": "57.28592"}
{"text": "The efficacy and safety of insulin degludec given in variable once - daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily : a 26-week , randomized , open - label , parallel - group , treat - to - target trial in individ .", "label": "", "metadata": {}, "score": "57.66455"}
{"text": "In addition , there were no differences in the amount of supplements of insulin glulisine ( 13 \u00b1 10 units ) and regular insulin ( 12 \u00b1 6 units ) ( NS ) .", "label": "", "metadata": {}, "score": "57.673428"}
{"text": "Insulin therapy for type 2 diabetes .Luigi F Meneghini University of Miami Miller School of Medicine , 1450 NW 10th Ave , Miami , FL 33136 , USA Endocrine 43:529 - 34 .", "label": "", "metadata": {}, "score": "57.708237"}
{"text": "10.1161/CIRCULATIONAHA.110.960138 .PubMed Central View Article PubMed .Garber AJ : Insulin intensification strategies in type 2 diabetes : when one injection is no longer sufficient .", "label": "", "metadata": {}, "score": "57.78277"}
{"text": "2007 , 29 ( Spec No ) : 1254 - 1270 .View Article .Jain SM , Mao X , Escalante - Pulido M , Vorokhobina N , Lopez I , Ilag LL : Prandial - basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia : initiate and progressively advance insulin therapy in type 2 diabetes .", "label": "", "metadata": {}, "score": "57.791702"}
{"text": "Individualized glycemic goal setting and establishing when and how to start insulin depend on 2 very important patient - specific aspects : clinical conditions ( age , duration of diabetes , presence of microvascular disease and comorbidities , and risk of severe hypoglycemia ) , and psychosocial / economic context .", "label": "", "metadata": {}, "score": "57.823097"}
{"text": "RESEARCH AND DESIGN METHODS -This 24-week , multicenter , randomized , controlled study compared two algorithms for adjusting mealtime ( glulisine ) insulin along with a standard algorithm for adjusting background ( glargine ) insulin in 273 intent - to - treat patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "57.979492"}
{"text": "View Article PubMed .Holman RR , Thorne KI , Farmer AJ , Davies MJ , Keenan JF , Paul S , Levy JC , 4-T Study Group : Addition of biphasic , prandial , or basal insulin to oral therapy in type 2 diabetes .", "label": "", "metadata": {}, "score": "58.098015"}
{"text": "View Article PubMed .Holman RR , Thorne KI , Farmer AJ , Davies MJ , Keenan JF , Paul S , Levy JC , 4-T Study Group : Addition of biphasic , prandial , or basal insulin to oral therapy in type 2 diabetes .", "label": "", "metadata": {}, "score": "58.098015"}
{"text": "10.2337/diaclin.23.2.78 .View Article .Ligthelm RJ , Gylvin T , DeLuzio T , Raskin P : A comparison of twice - daily biphasic insulin aspart 70/30 and once - daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy : a randomized , open - label study .", "label": "", "metadata": {}, "score": "58.21257"}
{"text": "The use of rapid - acting insulin analogues for the mealtime bolus , which when combined with intermediate - acting insulin , can reduce the risk of hypoglycemia and the need for snacks between meals [ 56 ] .", "label": "", "metadata": {}, "score": "58.217796"}
{"text": "PubMed View Article .Hollander P , Cooper J , Bregnhoj J , Pedersen CB : A 52-week , multinational , open - label , parallel - group , noninferiority , treat - to - target trial comparing insulin detemir with insulin glargine in a basal - bolus regimen with mealtime insulin aspart in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "58.278076"}
{"text": "PubMed View Article .Rosenstock J , Davies M , Home PD , Larsen J , Koenen C , Schernthaner G : A randomised , 52-week , treat - to - target trial comparing insulin detemir with insulin glargine when administered as add - on to glucose - lowering drugs in insulin - naive people with type 2 diabetes .", "label": "", "metadata": {}, "score": "58.283344"}
{"text": "Demonstrating strategies for initiation of insulin therapy : matching the right insulin to the right patient .L Meneghini University of Miami Miller School of Medicine , Eleanor and Joseph Kosow Diabetes Treatment Center , Diabetes Research Institute , Miami , FL 33136 , USA Int J Clin Pract 62:1255 - 64 .", "label": "", "metadata": {}, "score": "58.29821"}
{"text": "PubMed View Article .Philis - Tsimikas A : An update on the use of insulin detemir , with a focus on type 2 diabetes ( drug evaluation update ) .", "label": "", "metadata": {}, "score": "58.3518"}
{"text": "As is the case with basal insulin , the dose of rapid - acting insulin should be titrated according to the titration sched- ule shown in Table 6 .", "label": "", "metadata": {}, "score": "58.357555"}
{"text": "In contrast , insulin glargine is a long - acting basal analog that provides insulin delivery over a 24-hour period without a pronounced . peak ( Figure 3B ) [ 13,14,31].", "label": "", "metadata": {}, "score": "58.456276"}
{"text": "This result suggests that metformin is safe and effective for treating obese children and adolescents with T2DM .On the other hand , nonobese patients tended to use SU or insulin .", "label": "", "metadata": {}, "score": "58.46733"}
{"text": "10.1007/s00125 - 009 - 1468 - 7 .View Article PubMed .Garber AJ , Wahlen J , Wahl T , Bressler P , Braceras R , Allen E , Jain R : Attainment of glycaemic goals in type 2 diabetes with once- , twice- , or thrice - daily dosing with biphasic insulin aspart 70/30 ( The 1 - 2 - 3 study ) .", "label": "", "metadata": {}, "score": "58.55135"}
{"text": "Comparison of 2 intensification regimens with rapid - acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once - daily insulin detemir and oral antidiabetes drugs : the step - wise randomized study .", "label": "", "metadata": {}, "score": "58.615227"}
{"text": "Patients treated with intravenous glulisine insulin were transitioned to glargine once daily and glulisine before meals .Treatment protocols .Orders for intravenous fluids , potassium , and bicarbonate administration were similar in both groups and followed current American Diabetes Association guidelines ( 2 , 8 ) .", "label": "", "metadata": {}, "score": "58.72627"}
{"text": "As the disease progresses , the majority of patients will require insulin to maintain HbA 1c at desired target levels .Insulin can be used concomitant to oral anti - diabetic medication / GLP-1 analogues and as a part of either a basal only or a basal - bolus regimen .", "label": "", "metadata": {}, "score": "58.73716"}
{"text": "PubMed View Article .Raskin P , Gylvin T , Weng W , Chaykin L : Comparison of insulin detemir and insulin glargine using a basal - bolus regimen in a randomized , controlled clinical study in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "58.776405"}
{"text": "The length of hospital stay was similar between patients treated with glargine and glulisine ( 2.9 \u00b1 2.2 days ) and NPH and regular insulin ( 3.3 \u00b1 2.2 days ) ( NS ) .", "label": "", "metadata": {}, "score": "58.799103"}
{"text": "Recent consensus conference recommendations from the American College of Endocrinology indicate that glycemic targets can be effectively achieved by basal insulin plus an OAD or basal- prandial insulin regimens in type 2 diabetes [ 12].", "label": "", "metadata": {}, "score": "58.82167"}
{"text": "Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine : clinical practice experience from a German subgroup of the PREDICTIVE st .", "label": "", "metadata": {}, "score": "58.83863"}
{"text": "Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine : clinical practice experience from a German subgroup of the PREDICTIVE st .", "label": "", "metadata": {}, "score": "58.83863"}
{"text": "Edelman SV : Incretins : what does the future hold ?Diabetes Tech- nol Ther 2005 , 7:809 - 812 .Edelman SV , Weyer C : Unresolved challenges with insulin ther- apy in type I and type 2 diabetes : potential benefit of replac- ing amylin , a second beta - cell hormone .", "label": "", "metadata": {}, "score": "58.845963"}
{"text": "10.1056/NEJMoa075392 .View Article PubMed .Raskin P , Allen E , Hollander P , Lewin A , Gabbay RA , Hu P , Bode B , Garber A B , INITIATE Study Group : Initiating insulin therapy in type 2 diabetes .", "label": "", "metadata": {}, "score": "58.85948"}
{"text": "10.1056/NEJMoa075392 .View Article PubMed .Raskin P , Allen E , Hollander P , Lewin A , Gabbay RA , Hu P , Bode B , Garber A B , INITIATE Study Group : Initiating insulin therapy in type 2 diabetes .", "label": "", "metadata": {}, "score": "58.85948"}
{"text": "Diabetes Obes Metab 7 : 73 -82 , 2005 .Holman RR , Thorne KI , Farmer AJ , Davies MJ , Keenan JF , Paul S , Levy JC , 4-T Study Group : Addition of biphasic , prandial , or basal insulin to oral therapy in type 2 diabetes .", "label": "", "metadata": {}, "score": "58.95771"}
{"text": "10.1111/j.1463 - 1326.2006.00622.x .View Article PubMed .Yki - Jarvinen H : Combination therapies with insulin in type 2 diabetes .Diabetes Care .", "label": "", "metadata": {}, "score": "59.004173"}
{"text": "In comparison to insulin analogs , this insulin formulation has a delayed onset of action , requiring it to be administered approxi- mately 30 minutes before mealtime in order to match its peak insulin effect to postprandial rises in blood glucose levels [ 13,14].", "label": "", "metadata": {}, "score": "59.020966"}
{"text": "Dosing and Titration of Basal - Prandial Insulin Therapy in Insulin - Naive Patients This section provides practical recommendations for initi- ating basal and prandial insulin in patients with type 2 diabetes who are not achieving glycemic targets on OADs alone .", "label": "", "metadata": {}, "score": "59.02552"}
{"text": "Practical Recommendations for Initiation of Basal Insulin Insulin - naive patients with type 2 diabetes who fail to achieve or maintain adequate glycemic control on OADs over 3 - 6 months should be started on basal insulin ther- apy .", "label": "", "metadata": {}, "score": "59.205666"}
{"text": "10.1007/s00125 - 006 - 0416-z .View Article PubMed .Rosenstock J , Dailey G , Massi - Benedetti M , Fritsche A , Lin Z , Salzman A : Reduced hypoglycaemia risk with insulin glargine .", "label": "", "metadata": {}, "score": "59.314907"}
{"text": "10.1007/s00125 - 006 - 0416-z .View Article PubMed .Rosenstock J , Dailey G , Massi - Benedetti M , Fritsche A , Lin Z , Salzman A : Reduced hypoglycaemia risk with insulin glargine .", "label": "", "metadata": {}, "score": "59.314907"}
{"text": "Patients ? with ? increasingly ? impaired ?\u03b2 - cell ? function as the disease progresses ultimately require insulin therapy .However , most obese patients do not need intensive insulin therapy using multiple daily injections , instead being managed with basal insulin support therapy in addition to an OHD or biphasic premix insulin .", "label": "", "metadata": {}, "score": "59.400455"}
{"text": "PubMed .Diabetes Obes Metab 2007 , 9 ( 3 ) : 418 - 427 .PubMed View Article .Fakhoury W , Lockhart I , Kotchie RW , Aagren M , Lereun C : Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti - diabetic therapy in patients with type-2 diabetes .", "label": "", "metadata": {}, "score": "59.543976"}
{"text": "Hermansen K , Madsbad S , Perrild H , Kristensen A , Axelsen M : Comparison of the soluble basal insulin analog insulin detemir with NPH insulin : a randomized open crossover trial in type 1 diabetic subjects on basal - bolus therapy .", "label": "", "metadata": {}, "score": "59.575626"}
{"text": "Pozzilli P , Di Mario U : Autoimmune diabetes not requiring insulin at diagnosis ( latent autoimmune diabetes of the adult ) : definition , characterization , and potential preven- tion .", "label": "", "metadata": {}, "score": "59.62697"}
{"text": "Explaining the significance of A1C measurements , discussing A1C goals , and sharing results is an important motivational tool for patients on insulin therapy [ 8].", "label": "", "metadata": {}, "score": "59.6642"}
{"text": "In patients who fail to achieve postprandial BG control with a basal insulin , premixed analogues can be an option in order to achieve [ 13 , 52 ] and maintain [ 51 ] overall glycemic control .", "label": "", "metadata": {}, "score": "59.82673"}
{"text": "Practical guidance to insulin management .Luigi Meneghini University of Miami Miller School of Medicine , Florida 33136 , USA Prim Care Diabetes 4:S43 - 56 .", "label": "", "metadata": {}, "score": "60.12716"}
{"text": "Important Limitations of Use : Lantus \u00ae is not recommended for the treatment of diabetic ketoacidosis .Important Safety Information for Lantus \u00ae ( insulin glargine injection ) 100 Units / mL .", "label": "", "metadata": {}, "score": "60.293503"}
{"text": "Important Limitations of Use : Lantus \u00ae is not recommended for the treatment of diabetic ketoacidosis .Important Safety Information for Lantus \u00ae ( insulin glargine injection ) 100 Units / mL .", "label": "", "metadata": {}, "score": "60.293503"}
{"text": "Due to the natural history of type 2 diabetes , many patients eventually progress to a level of insulin deficiency that requires initiation of prandial insulin ( or pharmaco- therapy targeted to prandial insulin control ) in addition . to basal insulin .", "label": "", "metadata": {}, "score": "60.29497"}
{"text": "View Article PubMed .Kazda C , Hulstrunk H , Helsberg K , Langer F , Forst T , Hanefeld M : Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine : a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy .", "label": "", "metadata": {}, "score": "60.33146"}
{"text": "Accordingly , in this study we aimed to compare differences between treatment with basal bolus insulin analogs and NPH and regular insulin after resolution of DKA .", "label": "", "metadata": {}, "score": "60.437004"}
{"text": "Data were collected from the medical records for all studied variables and for total insulin dose administered , number of injections and changes in body weight during the monitoring period .", "label": "", "metadata": {}, "score": "60.457882"}
{"text": "Data were collected from the medical records for all studied variables and for total insulin dose administered , number of injections and changes in body weight during the monitoring period .", "label": "", "metadata": {}, "score": "60.457882"}
{"text": "The American Diabetes Association recommends the transition to NPH and regular insulin twice daily or to a multidose regimen of short- or rapid - acting and intermediate- or long - acting insulins ( 2 , 8 ) .", "label": "", "metadata": {}, "score": "60.621597"}
{"text": "PubMed View Article .Dornhorst A , Luddeke HJ , Koenen C , Merilainen M , King A , Robinson A , et al .: Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal - only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia : 14-week follow - up data from PREDICTIVE .", "label": "", "metadata": {}, "score": "60.622013"}
{"text": "DeFronzo R , Goodman AM : The multicenter metformin study group : Efficacy of metformin in patients with non - insulin diabetes mellitus .N Engl J Med .", "label": "", "metadata": {}, "score": "60.627914"}
{"text": "DeFronzo R , Goodman AM : The multicenter metformin study group : Efficacy of metformin in patients with non - insulin diabetes mellitus .N Engl J Med .", "label": "", "metadata": {}, "score": "60.627914"}
{"text": "10.1111/j.1463 - 1326.2008.00915.x .View Article PubMed .Diabetes Care . 10.2337/dc08 - 2117 .PubMed Central View Article PubMed .Wolffenbuttel BH , Klaff LJ , Bhushan R , Fahrbach JL , Jiang H , Martin S : Initiating insulin therapy in elderly patients with Type 2 diabetes : efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose - lowering agents .", "label": "", "metadata": {}, "score": "60.703354"}
{"text": "[Medline ] [ CrossRef ] 9 .Sugihara S , Sasaki N , Kohno H , Amemiya S , Tanaka T , Matsuura N. The Committee for the Medical Treatment of Childhood - Onset Type 2 Diabetes , The Japanese Society for Pediatric Endocrinology .", "label": "", "metadata": {}, "score": "60.72228"}
{"text": "Upon entry into the study , 37 % were using glargine and at least one injection of a rapid - acting insulin analog , 36 % were using a premixed insulin , and the remainder were using a mix of various other regimens .", "label": "", "metadata": {}, "score": "60.779823"}
{"text": "Insulin detemir can be admin- istered once daily with the evening meal or at bedtime or twice daily with a morning dose and an evening dose 12 hours later .", "label": "", "metadata": {}, "score": "60.788155"}
{"text": "Four?received ? insulin .At the time of the study , metformin alone or in combination with an additional medication was frequently prescribed ; i.e. , 6 patients were treated with metformin alone , and 9 were treated with metformin and an additional OHD such as an?\u03b1 - GI , ? the?SU?glimepiride , ? the?thiazolidinedione ?", "label": "", "metadata": {}, "score": "60.79442"}
{"text": "Discussion .This study contributes with real - life evidence of dose similarities between DET and GLAR in T2D patients in Denmark .No differences in daily doses of DET and GLAR were identified when administered once daily and when taking into account different factors that may influence insulin utilisation .", "label": "", "metadata": {}, "score": "60.80035"}
{"text": "RESULTS There were no differences in the mean duration of treatment or in the amount of insulin infusion until resolution of DKA between intravenous treatment with regular and glulisine insulin .", "label": "", "metadata": {}, "score": "60.82141"}
{"text": "A retrospective multicentre parallel two - arm study included 301 patients with type 2 diabetes already on treatment with biphasic human insulin twice daily ( bd ) in combination with OAD .", "label": "", "metadata": {}, "score": "60.865715"}
{"text": "A retrospective multicentre parallel two - arm study included 301 patients with type 2 diabetes already on treatment with biphasic human insulin twice daily ( bd ) in combination with OAD .", "label": "", "metadata": {}, "score": "60.865715"}
{"text": "Diabetes 1995 , 44:1249 - 1258 .JAMA 1999 , 281:2005 - 2012 .II .Diabetes Core 2002 , 25:330 - 336 .LeahyJL : Intensive insulin therapy in type I diabetes mellitus .", "label": "", "metadata": {}, "score": "60.874992"}
{"text": "Currently at Novo Nordisk Brazil .References .UK Prospective Diabetes Study ( UKPDS )Group : Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "60.918785"}
{"text": "The use of OHDs could differ between obese and nonobese children with T2DM .Page 2 .Urakami et al .2 pharmacologic therapies independently in these two patient groups at the pediatric clinic of Nihon University Hospital in Tokyo .", "label": "", "metadata": {}, "score": "60.973007"}
{"text": "Patients can learn to adjust mealtime insulin by either using a simple algorithm or learning to use insulin - to - carbohydrate ratios .Insulin - to - carbohydrate ratios allow flexibility in food choices and enable relatively precise matching of mealtime insulin needs but can seem complex and may be difficult for some patients to implement ( 10 , 11 ) .", "label": "", "metadata": {}, "score": "61.11911"}
{"text": "It also allows patients to detect hypoglycemia and to take corrective measures , such as an insulin dose adjustment [ 46 ] .The required frequency of self - monitoring depends on the patient 's disease state , the treatment regimen , the target level of glycemic control to be achieved , and physician judgment [ 47 ] .", "label": "", "metadata": {}, "score": "61.231102"}
{"text": "An insulin - to - carbohydrate ratio allows patients to adjust their insulin based on the amount of carbohydrate they choose to eat at a meal .", "label": "", "metadata": {}, "score": "61.277092"}
{"text": "This profile is what allows Lantus \u00ae to be dosed once daily as a patient 's basal insulin .Lantus \u00ae is a long - acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "61.277832"}
{"text": "PubMed View Article .Heintjes EM , Thomsen TL , Penning - van Beest FJ , Christensen TE , Herings RM : Glycemic control and long - acting insulin analog utilization in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "61.6689"}
{"text": "For patients taking multiple insulin injections the frequency of home glocose montiring should be at least 3 times daily .While there is n't a specific guideline for patients on less frequent or no insulin , glu- cose monitoring is useful in helping achieve glycemic goals and should be used with increased frequency when- ever modifications are made to the diabetes regimen .", "label": "", "metadata": {}, "score": "61.681866"}
{"text": "Insulin glargine dosing .The initial insulin glargine dose was calculated as 50 % of the prerandomization total daily insulin dose .Subsequently , dosing was titrated weekly according to the mean of the last 3 days of fasting self - monitored blood glucose ( SMBG )", "label": "", "metadata": {}, "score": "61.819954"}
{"text": "Changes in insulin strength , manufacturer , type , or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment .", "label": "", "metadata": {}, "score": "61.843075"}
{"text": "Changes in insulin strength , manufacturer , type , or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment .", "label": "", "metadata": {}, "score": "61.843075"}
{"text": "Conclusions .Dose similarities between insulin detemir and insulin glargine were seen in type 2 diabetes patients when administered once daily .Thus , the use of insulin detemir and insulin glargine is not associated with different medical costs if the price and treating algorithm are similar .", "label": "", "metadata": {}, "score": "61.86942"}
{"text": "After resolution of ketoacidosis , the transition to subcutaneous glargine and glulisine insulin resulted in glycemic control similar to that for NPH and regular insulin ; however , treatment with glargine and glulisine insulin is safer and is associated with a significantly lower rate of hypoglycemia .", "label": "", "metadata": {}, "score": "61.915115"}
{"text": "Some patients taking 1 daily dose of basal insulin ( NPH , detemir , or glargine ) may not achieve the proposed A1C targets due to postprandial hyperglycemia despite appropriate fasting BG levels .", "label": "", "metadata": {}, "score": "62.022575"}
{"text": "Several strategies for insulin therapy in addition to oral AHAs can be used : neutral protamine Hagedorn ( NPH ) insulin , basal insulin analogues ( detemir or glargine ) , or premixed insulins .", "label": "", "metadata": {}, "score": "62.028908"}
{"text": "PubMed View Article .Hermansen K , Davies M , Derezinski T , Martinez RG , Clauson P , Home P : A 26-week , randomized , parallel , treat - to - target trial comparing insulin detemir with NPH insulin as add - on therapy to oral glucose - lowering drugs in insulin - naive people with type 2 diabetes .", "label": "", "metadata": {}, "score": "62.038147"}
{"text": "Authors ' contributions .All authors read and approved the final manuscript .UK Prospective Diabetes Study ( UKPDS )Group : Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "62.05345"}
{"text": "Insulin glargine may be safely administered either at bedtime or in the morning .As long as adminis- tration is at 24-hour intervals , the time of administration can be tailored for patient convenience or preference .", "label": "", "metadata": {}, "score": "62.232513"}
{"text": "In the present study , we found positive effects on glycemic control in some patients regardless of obesity .Stimulating endogenous insulin secretion in a glucose- dependent fashion and suppressing pancreatic glucagon output have major effects on lowering blood glucose .", "label": "", "metadata": {}, "score": "62.248787"}
{"text": "Insulin adherence may be improved through better provider communication regarding risks , shared decision making , and insulin self - management training .Intensification of insulin therapy is often required in patients with T2DM .", "label": "", "metadata": {}, "score": "62.26637"}
{"text": "JAMA 2003 , 289:2254 - 2264 [ 14].and nocturnal hypoglycemia are lower with insulin ana- logs [ 6,29].Bedtime dosing of NPH may predispose patients to nocturnal hypoglycemia , while morning dos- ing of NPH may predispose patients to late - morning and early afternoon hypoglycemia [ 13].", "label": "", "metadata": {}, "score": "62.440655"}
{"text": "No other covariates included in the models showed robust statistical correlation with daily insulin dose .Neither concomitant insulin use nor use of non - insulin anti - diabetic medication was significant .", "label": "", "metadata": {}, "score": "62.456955"}
{"text": "Finally , patients with type 2 diabetes on split - mixed or premixed twice - daily insulin regimens who are unable to achieve or maintain target A1C goals may also benefit from conversion to basal - prandial insulin regimens [ 14].", "label": "", "metadata": {}, "score": "62.52817"}
{"text": "Algorithm for premixed insulin titration - adjustment according to postprandial glucose [ 54 ] .Treatment regimens of patients on concomitant AHAs should be handled with caution because adjustments in AHA doses may be required to reduce the incidence of hypoglycemia when using premixtures [ 20 , 63 ] .", "label": "", "metadata": {}, "score": "62.619255"}
{"text": "UK Prospective Diabetes Study Group : Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "62.642197"}
{"text": "Garg SK , Rosenstock J , Ways K : Optimized basal - bolus insulin regimens in type 1 diabetes : insulin glulisine versus regular human insulin in combination with basal insulin glargine .", "label": "", "metadata": {}, "score": "62.91443"}
{"text": "Establishing the optimal mealtime insulin dose in basal - bolus therapy may be difficult because it often involves calculations that consider multiple factors such as current blood glucose , target blood glucose , insulin - to - carbohydrate ratios , total carbohydrate content of meals , and activity levels ( 7 ) .", "label": "", "metadata": {}, "score": "62.934105"}
{"text": "Several insulin preparations are now available for prandial coverage , including the short - acting regular human insulin , the recently available inhaled insulin , and the rapid - acting analogs , insulin lispro , insu- lin aspart , and insulin glulisine [ 13,14,30].", "label": "", "metadata": {}, "score": "62.95124"}
{"text": "Malone JK , Bai S , Campaigne BN , Reviriego J , Augendre - Ferrante B : Twice - daily pre - mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes .", "label": "", "metadata": {}, "score": "63.022644"}
{"text": "If subsequent monitoring clearly shows prompt loss of control , the original dosages of OADs should be resumed .Once prandial insulin is added to basal insulin therapy , secretagogues ( eg , sulfonylureas ) may be discon- tinued .", "label": "", "metadata": {}, "score": "63.066635"}
{"text": "Patients treated with LM50 who are usually receiving TID doses should adjust the premixed insulin dose every 3 to 4 days ( twice a week ) , as shown in Table 4 .", "label": "", "metadata": {}, "score": "63.099895"}
{"text": "Lantus \u00ae is a long - acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "63.126026"}
{"text": "Using capillary glucose monitoring to adjust doses of premixed insulin .Measurement of capillary glucose levels performed by patients themselves ( self - monitoring ) is an important tool in assessing BG levels and making the required adjustments to treatment to facilitate improved glycemic control [ 45 ] .", "label": "", "metadata": {}, "score": "63.15356"}
{"text": "2009 , 11 ( Suppl 5 ) : 14 - 18 .View Article PubMed .Garber AJ : Premixed insulin analogues for the treatment of diabetes mellitus .", "label": "", "metadata": {}, "score": "63.1559"}
{"text": "Therapeutic approaches for T2DM at our clinic are shown in Table 1 .The majority of patients showed amelioration of hyperglycemia through diet and exercise modification during a relatively short period of 1 - 3 mo .", "label": "", "metadata": {}, "score": "63.182636"}
{"text": "However , premixed insulin analogues are more convenient and equally or more effective , despite being potentially associated with slightly greater weight gain and nonsevere hypoglycemic reactions [ 7 , 10 , 11 , 13 , 23 - 26 ] .", "label": "", "metadata": {}, "score": "63.21192"}
{"text": "To address this issue , a panel of clinical experts convened to develop practical recommendations on how to initiate basal- prandial therapy in patients with type 2 diabetes , focusing on patient selection , simple dosing and titration , and monitoring .", "label": "", "metadata": {}, "score": "63.257706"}
{"text": "Previous randomized studies in patients with DKA have focused on the amount and route of insulin administration during the acute resolution phase of ketoacidosis ( 2 , 3 ) .", "label": "", "metadata": {}, "score": "63.427658"}
{"text": "Lantus \u00ae is a once - daily , long - acting insulin that provides 24-hour basal coverage with no pronounced peak .1 Lantus \u00ae can provide effective glycemic control in diabetes patients as part of an overall diabetes treatment plan , which includes diet , exercise , and other diabetes medications .", "label": "", "metadata": {}, "score": "63.44159"}
{"text": "In : LeahyJL , Cefalu WT ( eds ) Insulin Therapy .Reproduced by permission of Routledge / Taylor & Francis Group , LLC . ing of planned meals is delayed and the patient is on NPH insulin [ 13,14].", "label": "", "metadata": {}, "score": "63.469414"}
{"text": "10.1111/j.1463 - 1326.2010.01287.x .PubMed Central View Article PubMed .Liebl A , Prusty V , Valensi P , Kawamori R , Christiansen JS , Palmer AJ , Balschmidt P , Ligthelm R , Mohan V : Ten years of experience with biphasic insulin aspart 30 : from drug development to the latest clinical findings .", "label": "", "metadata": {}, "score": "63.518288"}
{"text": "The existence of co - morbidities in T2D patients may influence insulin utilisation , but was not included in the multivariate regression models as data was not available .", "label": "", "metadata": {}, "score": "63.631348"}
{"text": "In a recent study , the basal analog insulin detemir given twice daily showed comparable efficacy to NPH insulin with significantly less nocturnal hypoglycemia [ 29].", "label": "", "metadata": {}, "score": "63.63391"}
{"text": "Patients should then administer the basal analog at bedtime .Starting the following morn- ing , a rapid - acting insulin may be provided at meal- time(s ) as needed .", "label": "", "metadata": {}, "score": "63.783234"}
{"text": "Although several controlled studies have shown that low - dose insulin therapy is effective regardless of the route of administration , most patients are treated with intravenous regular insulin until resolution of DKA ( 8 ) .", "label": "", "metadata": {}, "score": "63.786255"}
{"text": "10.4158/EP08308.ORR .View Article PubMed .Ilag LL , Kerr L , Malone JK , Tan MH : Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes : an evidence - based comparison .", "label": "", "metadata": {}, "score": "63.79868"}
{"text": "There are different compositions of premixed insulin options , depending on the amount of food consumed in each meal .The titration process is as previously described ( Table 3 ) .", "label": "", "metadata": {}, "score": "63.819435"}
{"text": "Various limitations of effective home - based BG self - monitoring should be taken into consideration .The Brazilian government aids patients with diabetes by providing the equipment and supplies ( glucometer and glucose test strips ) needed for BG self - monitoring for patients who are using insulin [ 48 ] .", "label": "", "metadata": {}, "score": "64.0259"}
{"text": "This regimen also requires fewer BG measurements during the day when compared with basal - bolus therapy , and ensures that the patient receives both basal insulin and bolus insulin at meals with 2 or a maximum of 3 injections per day [ 13 , 20 ] .", "label": "", "metadata": {}, "score": "64.05528"}
{"text": "The lower total insulin doses for the carb count group patients may reflect more matching of insulin doses to carbohydrate intake at each meal as opposed to the set meal doses of those in the simple algorithm group .", "label": "", "metadata": {}, "score": "64.13417"}
{"text": "Second step : postprandial monitoring .In cases in which the established treatment goal has not been achieved , it is suggested that paired measurements of BG before and after main meals be performed to define when the use of corrective dietary measures and/or a larger dosage of insulin is required .", "label": "", "metadata": {}, "score": "64.34722"}
{"text": "Secondary objectives were to examine for changes in fasting blood glucose ( FBG ) , body weight , treatment with OAD or fast - acting insulin and safety , by assessing the frequency and severity of hypoglycaemic episodes .", "label": "", "metadata": {}, "score": "64.387665"}
{"text": "Secondary objectives were to examine for changes in fasting blood glucose ( FBG ) , body weight , treatment with OAD or fast - acting insulin and safety , by assessing the frequency and severity of hypoglycaemic episodes .", "label": "", "metadata": {}, "score": "64.387665"}
{"text": "View Article PubMed .Douek IF , Allen SE , Ewings P , Gale EA , Bingley PJ : Continuing metformin when starting insulin in patients with Type 2 diabetes : a double - blind randomized placebo - controlled trial .", "label": "", "metadata": {}, "score": "64.461105"}
{"text": "Owens DR , Zinman B , Bolli GB : Insulins today and beyond .Lancet 2001 , 358:739 - 746 .New York , NY : Pfizer Inc. 33 .", "label": "", "metadata": {}, "score": "64.56222"}
{"text": "Publisher main menu .Follow BioMed Central .Diabetology & Metabolic Syndrome main menu .Intensification of insulin therapy in patients with type 2 diabetes : a retrospective , non- interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice .", "label": "", "metadata": {}, "score": "64.56529"}
{"text": "A transition to subcutaneous glargine and glulisine after resolution of DKA resulted in similar glycemic control but in a lower rate of hypoglycemia than with NPH and regular insulin .", "label": "", "metadata": {}, "score": "64.582504"}
{"text": "View Article PubMed .Hirsch IB , Bergenstal RM , Parkin CG , Wright E , Buse JB : A real - world approach to insulin therapy in primary care practice .", "label": "", "metadata": {}, "score": "64.62801"}
{"text": "Insulin glulisine dosing .Glulisine dose adjustment for both groups was based on prelunch / dinner and bedtime ( these three time points are referred to as mealtime ) blood glucose patterns from the previous week as shown in Table 1 .", "label": "", "metadata": {}, "score": "64.7535"}
{"text": "This trial evaluated the efficacy and safety of varying the daily injection time of insulin degludec ( IDeg ) , an ultra - long - acting basal insulin ... .", "label": "", "metadata": {}, "score": "64.82505"}
{"text": "The insulin dose was adjusted , and supplemental insulin was given based on blood glucose levels ( supplementary Table B , available in an online appendix ) .", "label": "", "metadata": {}, "score": "64.82514"}
{"text": "Urakami et al . 8 of incretin therapy in type 2 diabetes : systemic review and meta - analysis .JAMA 2007;298:194- 206 . [Medline ] [ CrossRef ] 16 .", "label": "", "metadata": {}, "score": "64.862976"}
{"text": "10.2337/diacare.26.11.3080 .View Article PubMed .Davies M , Storms F , Shutler S , Bianchi - Biscay M , Gomis R , ATLANTUS Study Group : Improvement of glycemic control in subjects with poorly controlled type 2 diabetes : comparison of two treatment algorithms using insulin glargine .", "label": "", "metadata": {}, "score": "64.95551"}
{"text": "10.2337/diacare.26.11.3080 .View Article PubMed .Davies M , Storms F , Shutler S , Bianchi - Biscay M , Gomis R , ATLANTUS Study Group : Improvement of glycemic control in subjects with poorly controlled type 2 diabetes : comparison of two treatment algorithms using insulin glargine .", "label": "", "metadata": {}, "score": "64.95551"}
{"text": "One of the main limitations of insulin therapy and the attainment of glycemic control is the weight gain associated with insulin treatment .It has been widely observed in numerous human insulin and premixed insulin studies [ 64 - 66 ] and can seriously affect patient compliance with treatment and thus , may adversely affect the prognosis .", "label": "", "metadata": {}, "score": "64.99606"}
{"text": "Furthermore , weight either decreases or remains stable , and serum lipid levels decrease during treatment .We recognized that metformin would be effective for most children with T2DM because more than 80 % of cases with childhood T2DM are obese and exhibit insulin resistance with hyperinsulinemia ( 7 , 8) .", "label": "", "metadata": {}, "score": "65.1013"}
{"text": "Competing interests .Insulin detemir is produced and marketed by Novo Nordisk .COWI has received funding from Novo Nordisk Scandinavia to conduct the analyses and to draft the manuscript .", "label": "", "metadata": {}, "score": "65.13444"}
{"text": "Figure 3 Basal - prandial insulin replacement profiles using ( A ) NPH plus regular human insulin and ( B ) insulin glargine plus a rapid - acting insulin .", "label": "", "metadata": {}, "score": "65.13811"}
{"text": "The combination of 2 or 3 noninsulin AHAs with different mechanisms of action is frequently used , since most patients are reluctant to start insulin .", "label": "", "metadata": {}, "score": "65.15039"}
{"text": "Only 2 patients independently received sulfonylureas ( SUs ) in the form of glimepiride .In addition , 9 patients were treated with basal insulin supported with oral hypoglycemic drugs ( OHDs ) or biphasic premix insulin .", "label": "", "metadata": {}, "score": "65.15796"}
{"text": "In Insulin Therapy Edited by : LeahyJL and Cefalu WT .New York , NY : Marcel Dekker Inc. ; 2002:1- II .Campbell RK , White JR Jr. : Insulin therapy in type 2 diabetes .", "label": "", "metadata": {}, "score": "65.289795"}
{"text": "Davies M , Storms F , Shutler S , Bianchi - Biscay M , Gomis R , Study Group : AT.LANTUS trial investigating treatment algorithms for insulin glargine ( LANTUS ) : results of the type 2 study [ abstract I 980-PO].", "label": "", "metadata": {}, "score": "65.440155"}
{"text": "Dimitrios Makrigiannis has received honoraria from NovoNordisk , Sanofi , Elli - Lilly and Novartis for memberships on the advisory boards and for speaking on subjects related to treatment with antidiabetic drugs and insulin .", "label": "", "metadata": {}, "score": "65.53987"}
{"text": "Dimitrios Makrigiannis has received honoraria from NovoNordisk , Sanofi , Elli - Lilly and Novartis for memberships on the advisory boards and for speaking on subjects related to treatment with antidiabetic drugs and insulin .", "label": "", "metadata": {}, "score": "65.53987"}
{"text": "Page 3 .Pharmacologic treatment in children with type 2 diabetes 3 more than 7.0 % ( NGSP ) , a variety of OHDs and/ or insulin injections were introduced depending on the patient 's condition .", "label": "", "metadata": {}, "score": "65.63235"}
{"text": "This prolonged duration can increase the risk of hypoglycemia if the tim- .Premixed : Comprised of intermediate - acting insulin with either regular human insulin or a rapid - acting analog in a fixed ratio ( eg , 70/30 ) ; thus , the onset , peak , and duration reflect the combined effect of these components .", "label": "", "metadata": {}, "score": "65.63601"}
{"text": "Wright A , Burden AC , Paisey RB , Cull CA , Holman RR , UK Prospective Diabetes Study Group : Sulfonylurea inadequacy : efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study ( UKPDS 57 ) .", "label": "", "metadata": {}, "score": "65.68855"}
{"text": "In : Leahy JL , Cefalu WT ( eds ) Insulin Therapy .Reproduced by permission of Routledge / Taylor & Francis Group , LLC [ 41].", "label": "", "metadata": {}, "score": "65.688934"}
{"text": "Meneghini L : Demonstrating strategies for initiation of insulin therapy : matching the right insulin to the right patient .Int J Clin Pract 2008 , 62 ( 8) : 1255 - 1264 .", "label": "", "metadata": {}, "score": "65.75707"}
{"text": "\u00a9 2002 - 2015 sanofi - aventis U.S. LLC .All rights reserved .US.GLA.15.09.005 Last Updated : October 2015 Abstract .OBJECTIVE To compare the safety and efficacy of insulin analogs and human insulins both during acute intravenous treatment and during the transition to subcutaneous insulin in patients with diabetic ketoacidosis ( DKA ) .", "label": "", "metadata": {}, "score": "65.96555"}
{"text": "In addition , recent evidence suggests that LM25 provides similar glycemic control to that of insulin lispro plus glargine in insulin - na\u00efve patients with uncontrolled diabetes on AHAs [ 55 ] .", "label": "", "metadata": {}, "score": "65.98369"}
{"text": "UK Prospective Diabetes Study ( UKPDS )Group : Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "66.11401"}
{"text": "Raslovi K , Bogoev M , Raz I , Leth G , Gall MA , Hancu N : Insulin detemir and insulin aspart : a promising basal - bolus regimen for type 2 diabetes .", "label": "", "metadata": {}, "score": "66.12406"}
{"text": "Only 2 patients were administered glimepiride alone .Nine patients received insulin therapy , 4 using metformin with basal insulin ( glargine ) support and 5 using biphasic premix insulin or multiple injections of insulin .", "label": "", "metadata": {}, "score": "66.15311"}
{"text": "Pediatr Int 2003;45:642 - 6 . [Medline ] [ CrossRef ] 7 .Urakami T , Kubota S , Nitadori Y , Harada K , Owada M , Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area .", "label": "", "metadata": {}, "score": "66.197556"}
{"text": "10.1111/j.1463 - 1326.2009.01165.x .View Article PubMed .Lasserson DS , Glasziou P , Perera R , Holman RR , Farmer AJ : Optimal insulin regimens in type 2 diabetes mellitus : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "66.23186"}
{"text": "10.1111/j.1463 - 1326.2009.01165.x .View Article PubMed .Lasserson DS , Glasziou P , Perera R , Holman RR , Farmer AJ : Optimal insulin regimens in type 2 diabetes mellitus : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "66.23186"}
{"text": "At the time of this study , patients were frequently treated with January 2013 Table 2 Antidiabetic medications in 26 obese children with T2DM RegimensN FemaleHbA1c ( % ) Insulin alone Insulin + Metformin Metformin alone Metformin ?", "label": "", "metadata": {}, "score": "66.27046"}
{"text": "New antidiabetic drugs , incretin mimetics and enhancers , appeared to be effective for some young patients , similar to the situation in adults with T2DM .", "label": "", "metadata": {}, "score": "66.3114"}
{"text": "Changes in insulin doses .At baseline , the mean insulin glulisine , insulin glargine , and total insulin doses were 53.9 , 53.9 , and 107.8 units ( simple algorithm ) and 50.5 , 50.5 , and 100.9 units ( carb count ) , respectively .", "label": "", "metadata": {}, "score": "66.320335"}
{"text": "Modified with permission from The American Diabetes Association . tlf any single blood glucose measurement is in this range , make the appropriate reduction in insulin dose .", "label": "", "metadata": {}, "score": "66.35212"}
{"text": "Table 6 .Number of daily rapid - acting insulin injections , biphasic or glargine insulin and total daily insulin dose after the end of the monitoring period .", "label": "", "metadata": {}, "score": "66.53943"}
{"text": "Table 6 .Number of daily rapid - acting insulin injections , biphasic or glargine insulin and total daily insulin dose after the end of the monitoring period .", "label": "", "metadata": {}, "score": "66.53943"}
{"text": "Insulin - treatment - na\u00efve patients .It is well established that patients with T2DM who do not achieve glycemic goals despite lifestyle changes , increased physical activity , and use of one or more AHAs should start treatment with insulin [ 8 , 9 ] .", "label": "", "metadata": {}, "score": "66.54224"}
{"text": "Study staff taught the carbohydrate counting ( carb count ) group about carbohydrate counting and how to use an insulin - to - carbohydrate ratio .", "label": "", "metadata": {}, "score": "66.6284"}
{"text": "In Brazil , there are currently 2 types of premixed insulins available : human insulin and analogue insulin ( Table 2 ) .Premixed insulin analogues have 2 components in their formulation : the prandial component is a rapid - acting analogue ( either insulin lispro or aspart ) , and the basal component is insulin lispro or aspart protamine suspension .", "label": "", "metadata": {}, "score": "66.786354"}
{"text": "Following initiation of insulin , patients should monitor FPG levels using home glucose monitoring .Insulin doses can be titrated according to self - monitored FPG values using a titration schedule such as that shown in Table 6[6].", "label": "", "metadata": {}, "score": "66.910706"}
{"text": "Continuous glucose monitor- ing is now available and is an important advancement in the management of diabetes since patients will have improved their ability to adjust insulin and to better antic- ipate and therefore prevent hypoglycemia [ 40].", "label": "", "metadata": {}, "score": "66.92456"}
{"text": "View Article PubMed .Diabetes Care .10.2337/diacare.28.11.2673 .View Article PubMed .Karter AJ , Subramanian U , Saha C , Crosson JC , Parker MM , Swain BE , Moffet HH , Marrero DG : Barriers to insulin initiation : the translating research into action for diabetes insulin starts project .", "label": "", "metadata": {}, "score": "66.925964"}
{"text": "Advantages of this regimen include the need for fewer BG measurements during the day while ensuring that the patient receives both basal insulin and bolus insulin at meals with 2 or a maximum of 3 injections per day [ 13 , 20 ] .", "label": "", "metadata": {}, "score": "66.985435"}
{"text": "Diabetes Care 2007;30:790 - 4 . [Medline ] [ CrossRef ] 13 .Weitgasser R , Lechleitner M , Luger A , Klinger A. Effect of glimepiride on HbA1c and body weight in type 2 diabetes : results of a 1.5-year follow - up study .", "label": "", "metadata": {}, "score": "66.987854"}
{"text": "None of the episodes of hypoglycemia in either group were associated with loss of consciousness or seizure .The TDD of subcutaneous insulin was similar between groups ( Table 3 ) .", "label": "", "metadata": {}, "score": "67.15097"}
{"text": "UK prospective diabetes study ( UKPDS ) group : Intensive blood glucose control with sulhonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "67.214294"}
{"text": "UK prospective diabetes study ( UKPDS ) group : Intensive blood glucose control with sulhonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "67.214294"}
{"text": "10.1111/j.1463 - 1326.2009.01165.x .View Article PubMed .Liebl A , Prager R , Binz K , Kaiser M , Bergenstal R , Gallwitz B : Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study : a randomized controlled trial .", "label": "", "metadata": {}, "score": "67.248375"}
{"text": "Frame 6 .Voiceover : This leads to the formation of micro precipitates , from which small amounts of Lantus \u00ae are slowly released .Insulin crystals exist in hexamer form .", "label": "", "metadata": {}, "score": "67.30935"}
{"text": "Basal insulin is considered an initial strategy ; however , premixed insulins are convenient and are equally or more effective , especially for patients who require both basal and prandial control but desire a more simplified strategy involving fewer daily injections than a basal - bolus regimen .", "label": "", "metadata": {}, "score": "67.37839"}
{"text": "10.1111/j.1464 - 5491.2005.01511.x .View Article PubMed .Land\u00f3 LF , Massari F , Oviedo A , Jiang H : R\u00e9gimen con insulina lispro mix 25 versus insulina glargina para la diabetes tipo 2 .", "label": "", "metadata": {}, "score": "67.48695"}
{"text": "Other agents for control of PPG include incretin mimetics ( eg , glucagon - like peptide-1 [ GLP-1 ] analogs ) and amylin analogs .Use of the GLP-1 analog exenatide reduces PPG and results in weight loss , however , it is not currently approved for use with insulin [ 33,34].", "label": "", "metadata": {}, "score": "67.5639"}
{"text": "Furthermore , significant or borderline significant differences were found in concomitant insulin use with more DET patients treated with Actrapid and more GLAR patients treated with Insuman Rapid .", "label": "", "metadata": {}, "score": "67.607735"}
{"text": "Russell - Jones D , Khan R : Insulin - associated weight gain in diabetes - causes , effects and coping strategies .Diabetes Obes Metab .", "label": "", "metadata": {}, "score": "67.64478"}
{"text": "The combination of basal and rapid - acting insulin analogs represents a more physiological approach to glucose control in the hospital .Glulisine has a faster onset of action and a shorter duration of action after subcutaneous injection compared with regular insulin ( 21 , 22 ) .", "label": "", "metadata": {}, "score": "67.78609"}
{"text": "\u03b2 - cell ? apoptosis?due?to?oxidative?stress ?This ? drug also carries a high risk of hypoglycemia and accelerated weight gain .On the other hand , while having a lower capacity to bind SU receptors on KATP channels , glimepiride exerts extrapancreatic effects such as decreased glucose output from the liver and enhanced sensitivity of peripheral tissues to insulin ( 11 ) .", "label": "", "metadata": {}, "score": "67.80481"}
{"text": "The nonobese patients tended to require pharmacologic therapies , in particular insulin , at an earlier stage of diabetes as compared with the obese patients .", "label": "", "metadata": {}, "score": "67.80891"}
{"text": "Type 2 diabetes in children and adolescents .Pediatr Diabetes 2009;10:17 - 32 . [CrossRef ] 4 .Urakami T. How should we treat type 2 diabetes in youth ?", "label": "", "metadata": {}, "score": "67.93245"}
{"text": "Rationale for Basal - Prandial Insulin Therapy Both basal and postprandial glucose ( PPG ) excursions contribute to hyperglycemia in type 2 diabetes , and treat- ment strategies that address both components may enhance attainment of glycemic goals .", "label": "", "metadata": {}, "score": "67.97682"}
{"text": "Abbreviations .DET : . insulin detemir .GLAR : . insulin glargine .NPH : . neutral protamine Hagedorn insulin .T2D : . type 2 diabetes .", "label": "", "metadata": {}, "score": "67.99295"}
{"text": "View Article PubMed .Heller S : Weight gain during insulin therapy in patients with type 2 diabetes mellitus .Diabetes Res Clin Pract .2004 , 65 ( Suppl 1 ) : S23-S27 .", "label": "", "metadata": {}, "score": "68.04344"}
{"text": "Ahmann AJ , Riddle MC : Insulin therapy in type 2 diabetes mel- litus .In Insulin Therapy Edited by : Leahy JL and Cefalu WT .", "label": "", "metadata": {}, "score": "68.11254"}
{"text": "PubMed Central View Article PubMed .Copyright .\u00a9 Tambascia et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. Abstract Basal - prandial insulin therapy is a physiologic approach to insulin delivery that utilizes multiple daily injections to cover both basal ( ie , overnight fasting and between - meal ) and prandial ( ie , glucose excursions above basal at mealtime ) insulin needs .", "label": "", "metadata": {}, "score": "68.58027"}
{"text": "10.1111/j.1463 - 1326.2006.00605.x .View Article PubMed .Diabetologia .2006 , 49 ( Suppl 1 ) : 603 - 604 .Rosenstock J , Ahmann AJ , Colon G , Scism - Bacon J , Jiang H , Martin S : Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents : prandial premixed ( insulin lispro protamine suspension / lispro ) versus basal / bolus ( glargine / lispro ) therapy .", "label": "", "metadata": {}, "score": "68.59117"}
{"text": "Premixed insulin analogues do not have 2 distinct peaks [ 26 , 42 - 44 ] .Once absorbed , the time of action corresponds to the rapid onset of action , and the duration of action corresponds to the intermediate insulin component .", "label": "", "metadata": {}, "score": "68.64456"}
{"text": "Most insulin - na\u00efve patients and their physicians are reluctant to transition to insulin treatment [ 21 ] .The reluctance to begin insulin treatment comes from the perception that the treatment regimen is complex ; however , the decision to start insulin may be based on insufficient information .", "label": "", "metadata": {}, "score": "68.683525"}
{"text": "The analyses confirmed the expected positive correlation between number of daily injections and daily insulin dose as well as dose similarities between DET and GLAR when administered twice daily ( data not shown ) .", "label": "", "metadata": {}, "score": "68.6866"}
{"text": "Inhaled insulin is currently available as 1-mg and 3-mg blisters ( equivalent to 3 U and 8 U of SC regular human insulin , respectively ) .", "label": "", "metadata": {}, "score": "68.78803"}
{"text": "View Article PubMed .Lasserson DS , Glasziou P , Perera R , Holman RR , Farmer AJ : Optimal insulin regimens in type 2 diabetes mellitus : systematic review and meta - analyses .", "label": "", "metadata": {}, "score": "68.80708"}
{"text": "These findings indicate that a basal bolus insulin regimen with glargine and glulisine is safer and should be preferred over NPH and regular insulin after the resolution of DKA .", "label": "", "metadata": {}, "score": "68.90567"}
{"text": "10.1056/NEJMoa0905479 .View Article PubMed .Fritsche A , Larbig M , Owens D , H\u00e4ring HU , GINGER study group : Comparison between a basal - bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study .", "label": "", "metadata": {}, "score": "68.99959"}
{"text": "10.1056/NEJMoa0905479 .View Article PubMed .Fritsche A , Larbig M , Owens D , H\u00e4ring HU , GINGER study group : Comparison between a basal - bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study .", "label": "", "metadata": {}, "score": "68.99959"}
{"text": "Biphasic human insulin Insulin glargine Glycaemic control Hypoglycaemia Body weight .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "69.319336"}
{"text": "Biphasic human insulin Insulin glargine Glycaemic control Hypoglycaemia Body weight .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "69.319336"}
{"text": "View Article PubMed .Diabetes Care . 10.2337/dc12 - 0413 .PubMed Central View Article PubMed .Riddle MC , Rosenstock J , Gerich J , Insulin Glargine 4002 Study Investigators : The treat - to - target trial : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients .", "label": "", "metadata": {}, "score": "69.33937"}
{"text": "View Article PubMed .Diabetes Care . 10.2337/dc12 - 0413 .PubMed Central View Article PubMed .Riddle MC , Rosenstock J , Gerich J , Insulin Glargine 4002 Study Investigators : The treat - to - target trial : randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients .", "label": "", "metadata": {}, "score": "69.33937"}
{"text": "Ideally , patients should have access to a certi- fied diabetes educator , instructional classes , and/or sup- port groups that can instruct them on home glucose . monitoring .", "label": "", "metadata": {}, "score": "69.46685"}
{"text": "However , almost 40 % of the participants in the control and 54 % of the participants in the active group needed 3or more insulin injections per day .", "label": "", "metadata": {}, "score": "69.528465"}
{"text": "However , almost 40 % of the participants in the control and 54 % of the participants in the active group needed 3or more insulin injections per day .", "label": "", "metadata": {}, "score": "69.528465"}
{"text": "PubMed Central View Article PubMed .Malone JK , Kerr LF , Campaigne BN , Sachson RA , Holcombe JH : Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin : a 16-week , randomized , open - label , crossover study in patients with type 2 diabetes beginning insulin therapy .", "label": "", "metadata": {}, "score": "69.54005"}
{"text": "Determine the total daily dose of regular human insulin .Example : A patient on 50 U premixed 70/30 ( NPH 35 U ; reg- ular human insulin 15 U twice daily ) .", "label": "", "metadata": {}, "score": "69.567924"}
{"text": "View Article PubMed .Exp Clin Endocrinol Diabetes .10.1055/s-2006 - 924424 .View Article PubMed .Fritsche A , Larbig M , Owens D , Haring HU : Comparison between a basal - bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study .", "label": "", "metadata": {}, "score": "69.60834"}
{"text": "Table 2 . T2D patient characteristics by basal long - acting insulin analogue DET and GLAR .Multivariate regression analysis .The results of the multivariate regression analyses are reported in Table 3 .", "label": "", "metadata": {}, "score": "69.65608"}
{"text": "Adverse events , hypoglycemic episodes , and concomitant medications were recorded .There was weekly contact either by a study visit or a phone call to review diaries and adjust insulin doses .", "label": "", "metadata": {}, "score": "69.670456"}
{"text": "Abstract .OBJECTIVE -Carbohydrate counting is an effective approach to mealtime insulin adjustment in type 1 diabetes but has not been rigorously assessed in type 2 diabetes .", "label": "", "metadata": {}, "score": "69.75308"}
{"text": "Patients with premeal glucose levels outside the 90 - 130 mg / dL range may have dietary factors that are impacting their glucose levels or simply require more insulin .", "label": "", "metadata": {}, "score": "69.84671"}
{"text": "Prandial insulin is added to the regimens of patients not achieving glycemic goals despite well - controlled fasting blood glucose after 3 - 6 months of basal insulin therapy ( Figure 2 ) [ 14].", "label": "", "metadata": {}, "score": "70.0669"}
{"text": "Calculating the initial basal insulin analog dose .Example : A patient on 50 U premixed 70/30 ( NPH 35 U ; reg- ular human insulin 15 U ) twice daily .", "label": "", "metadata": {}, "score": "70.11388"}
{"text": "10.2337/diacare.26.3.881 .View Article PubMed .Scheen AJ , Rosenstock J , Schmitt H , Jiang HH , Ivanyi T : Monnier 's hypothesis revisited : postprandial ( PPG ) vs fasting ( FPG ) hyperglycaemia at baseline and response to basal or premixed insulin stratified by HbA1c target achieved [ abstract].", "label": "", "metadata": {}, "score": "70.15881"}
{"text": "This usually occurs when the patient has adequate BG concentrations at night and early morning , but experiences daytime hyperglycemia , in which case treatment with insulin only is recommended [ 10 ] .", "label": "", "metadata": {}, "score": "70.18759"}
{"text": "The insulin dose was given as two - thirds NPH and one - third regular insulin in the morning with breakfast and two - thirds NPH and one - third regular insulin in the evening with dinner .", "label": "", "metadata": {}, "score": "70.26132"}
{"text": "Diabetes 2002 , 51:1083 - 1087 .Hirsch IB : Optimal initiation of insulin in type 2 diabetes .Med- scope General Medicine 2005:7 .Naik RG , Palmer JP : Latent autoimmune diabetes in adults ( LADA ) .", "label": "", "metadata": {}, "score": "70.496925"}
{"text": "Pharmacologic treatment in children with type 2 diabetes 5 including DPP4-I and GLP-1 receptor agonist ( Fig . 1 ) .In regards to SU , glibenclamide has been widely used not only in adults but also in children and adolescents with T2DM as a first OAD .", "label": "", "metadata": {}, "score": "70.707085"}
{"text": "The expert panel meeting which provided the basis for the recommendations in this article was supported by an edu- cational grant from sanofi - aventis .", "label": "", "metadata": {}, "score": "70.98889"}
{"text": "10.1136/bmj.321.7258.405 .PubMed Central View Article PubMed .International Diabetes Federation : Glucose control : insulin therapy .Global Guideline for Type 2 Diabetes .", "label": "", "metadata": {}, "score": "71.048546"}
{"text": "It is important to educate patients about symptoms associated with hypoglycemia ( Table 3 ) .and common causes , including failure to eat after taking insulin , overaggressive use of insulin ( ie , increasing the insulin dose in response to an anomalous blood glucose concentration ) , overexercising without adjusting the insu- lin dose , and alcohol consumption [ 8,28].", "label": "", "metadata": {}, "score": "71.09932"}
{"text": "New York , NY : Marcel Dekker , Inc. ; 2002:87 - 112 .DeWitt DE , Hirsch IB : Outpatient insulin therapy in type I and type 2 diabetes mellitus : scientific review .", "label": "", "metadata": {}, "score": "71.11998"}
{"text": "Patients on these regimens can be directly converted to a basal - prandial approach using the protocol described below .In addition , because patient reluctance to use needles has already been overcome in this group , it might be easier to transition patients to mul- tiple daily injections , if necessary .", "label": "", "metadata": {}, "score": "71.21976"}
{"text": "Statistical analysis .Based on previous reports , the rate of hypoglycemic events ( primary end point ) in patients treated with subcutaneous NPH and regular insulin was estimated to be 37 % ( 3 , 9 ) .", "label": "", "metadata": {}, "score": "71.24541"}
{"text": "10.2337/dc09 - 1184 .PubMed Central View Article PubMed .Hirsch IB , Yuan H , Campaigne BN , Tan MH : Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients .", "label": "", "metadata": {}, "score": "71.279564"}
{"text": "Whereas LM25 can be used for patients who have not reached adequate postprandial BG concentrations ( 13,14,52 ) , LM50 can be used to enhance premixed insulin treatments and is a good choice for patients who are already using premixed analogues [ 53 ] .", "label": "", "metadata": {}, "score": "71.32258"}
{"text": "New antidiabetic drugs , DPP-4 inhibitors and GLP-1 receptor agonists , seemed to exert positive effects on glycemic control without occurrence of hypoglycemic episodes in some patients regardless of the type of diabetes .", "label": "", "metadata": {}, "score": "71.39241"}
{"text": "It might be a good alternative for people whose control is inadequate with AHAs and/or basal insulin , particularly those patients with postprandial hyperglycemia or high A1C. Similarly , insulin premixes can be the appropriate choice for patients requiring both components of treatment ( basal and bolus ) but who have restrictions based on the complexity of the basal - bolus regimen .", "label": "", "metadata": {}, "score": "71.40343"}
{"text": "Patients taking metformin at randomization continued using it at the same dose .No other insulin or oral antidiabetic agents were permitted .Dietary and lifestyle recommendations .", "label": "", "metadata": {}, "score": "71.529755"}
{"text": "The mean value of HbA1c in the obese patients with pharmacologic therapies was 6.8 \u00b1 0.7 % ( NGSP ) .Pharmacologic therapies in children with nonobese T2DM On the other hand , the majority of the 23 nonobese patients were initially treated with SU alone or insulin ; i.e. , 8 patients were treated with SU alone , and 9 received insulin therapy .", "label": "", "metadata": {}, "score": "71.65474"}
{"text": "The inadequate duration of action of NPH insulin and an undesirable peak activity at 4 - 6 h after injection ( 10 ) as well as the high day - to - day variability in absorption ( 11 ) partially explains the high rate of hypoglycemic events .", "label": "", "metadata": {}, "score": "71.707504"}
{"text": "This investigator - initiated study was supported by an unrestricted grant from sanofi - aventis ( Bridgewater , NJ ) .G.E.U. is supported by research grants from the American Diabetes Association ( 7 - 03-CR-35 ) and the National Institutes of Health ( U01 DK074556 - 01 and Clinical and Translational Science Award [ General Clinical Research Center ] M01 RR-00039 ) .", "label": "", "metadata": {}, "score": "71.71245"}
{"text": "Bullano MF , Al - Zakwani IS , Fisher MD , Menditto L , Willey VJ : Differences in hypoglycemia event rates and associated cost - consequence in patients initiated on long - acting and intermediate - acting insulin products .", "label": "", "metadata": {}, "score": "72.06693"}
{"text": "Medline ] [CrossRef ] 12 .Gottschalk M , Danne T , Vlajnic A , Cara JF .Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "72.25061"}
{"text": "Diabetes Care . 10.2337/diacare.28.2.260 .View Article PubMed .Holman RR , Farmer AJ , Davies MJ , Levy JC , Darbyshire JL , Keenan JF , Paul SK , 4-T Study Group : Three - year efficacy of complex insulin regimens in type 2 diabetes .", "label": "", "metadata": {}, "score": "72.33159"}
{"text": "Diabetes Care . 10.2337/diacare.28.2.260 .View Article PubMed .Holman RR , Farmer AJ , Davies MJ , Levy JC , Darbyshire JL , Keenan JF , Paul SK , 4-T Study Group : Three - year efficacy of complex insulin regimens in type 2 diabetes .", "label": "", "metadata": {}, "score": "72.33159"}
{"text": "Luigi Fernando Meneghini .Summary .Publications .Why and how to use insulin therapy earlier in the management of type 2 diabetes .Luigi Meneghini Eleanor and Joseph Kosow Diabetes Treatment Center , Diabetes Research Institute , Miami , FL 33136 , USA South Med J 100:164 - 74 .", "label": "", "metadata": {}, "score": "72.58189"}
{"text": "Diabetes Care . 10.2337/dc10 - 1710 .PubMed Central View Article PubMed .Buse JB , Wolffenbuttel BH , Herman WH , Hippler S , Martin SA , Jiang HH , Shenouda SK , Fahrbach JL : The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy ( DURABLE ) trial : comparing the durability of lispro mix 75/25 and glargine .", "label": "", "metadata": {}, "score": "72.671555"}
{"text": "On the one hand , concomitant insulin use and use of non - insulin anti - diabetic medication are correlated with disease severity and thus daily dose of DET or GLAR .", "label": "", "metadata": {}, "score": "72.75923"}
{"text": "The results of this study are consistent with recent real - world studies from Europe and the US , which also did not find any significant dose differences between DET and GLAR in T2D patients [ 19 - 21 ] .", "label": "", "metadata": {}, "score": "72.8391"}
{"text": "Among these patients , 26 obese and 23 nonobese children were assigned to pharmacologic therapies during the course of diabetes .Pharmacologic therapies were started if the HbA1c ( NGSP ) value exceeded 7.0 % despite dietary and exercise management .", "label": "", "metadata": {}, "score": "72.88065"}
{"text": "Bonora E , Muggeo M : Postprandial blood glucose as a risk fac- tor for cardiovascular disease in Type II diabetes : the epide- miological evidence .", "label": "", "metadata": {}, "score": "73.03403"}
{"text": "We demonstrated pharmacologic therapies would currently be available even for children and adolescents with T2DM , and that the efficacies of these regimens apparently differ between obese and nonobese cases .", "label": "", "metadata": {}, "score": "73.072586"}
{"text": "The evaluation of the change in the proportion of patients receiving orally administered antidiabetic treatment from the start until the end of the monitoring period was performed by means of McNemar test .", "label": "", "metadata": {}, "score": "73.17795"}
{"text": "The evaluation of the change in the proportion of patients receiving orally administered antidiabetic treatment from the start until the end of the monitoring period was performed by means of McNemar test .", "label": "", "metadata": {}, "score": "73.17795"}
{"text": "The recent guidelines for the management of T2DM suggest that not all patients need or benefit from aggressive glucose management and that it is important to individualize treatment targets [ 15 ] .", "label": "", "metadata": {}, "score": "73.1991"}
{"text": "The recent guidelines for the management of T2DM suggest that not all patients need or benefit from aggressive glucose management and that it is important to individualize treatment targets [ 15 ] .", "label": "", "metadata": {}, "score": "73.1991"}
{"text": "Likewise , in other studies evaluating intensive therapy versus conventional therapy [ 34 - 36 ] , weight gain was generally greater in patients treated with intensive therapy .", "label": "", "metadata": {}, "score": "73.24082"}
{"text": "The simple algorithm group was provided set doses of glulisine to take before each meal .The carbohydrate counting ( carb count ) group was provided an insulin - to - carbohydrate ratio to use for each meal and adjusted their glulisine dose based on the amount of carbohydrate consumed .", "label": "", "metadata": {}, "score": "73.29529"}
{"text": "Pharmacologic treatment in children with type 2 diabetes 7 agonists .Furthermore , for the nonobese patients , GLP-1 agonists might protect against ongoing deterioration?of?\u03b2 - cell?function?by?suppressing ? apoptosis and promoting regeneration ( 18 ) .", "label": "", "metadata": {}, "score": "73.31471"}
{"text": "Diabetes Care 2002 , 25:275 - 278 .US Food and Drug Administration : New device approval : Dex- Com STS Continuous Glucose Monitoring System - P050012 .", "label": "", "metadata": {}, "score": "73.41763"}
{"text": "10.1056/NEJMoa0706245 .View Article PubMed .Effect of intensive blood - glucose control with metformin on complications in overweight patients with type 2 diabetes ( UKPDS 34 ) .", "label": "", "metadata": {}, "score": "73.42565"}
{"text": "Table 3 .Multivariate regression models of daily dose of long - acting insulin analogue DET and GLAR ( U / kg ) .The correlation between BMI and insulin dose is well - established .", "label": "", "metadata": {}, "score": "73.61699"}
{"text": "The aim of this study was - in routine clinical settings in Denmark - to compare daily doses of DET and GLAR in T2D patients when administered once daily .", "label": "", "metadata": {}, "score": "73.7285"}
{"text": "View Article .Holman RR , Paul SK , Bethel MA , Matthews DR , Neil HA : 10-year follow - up of intensive glucose control in type 2 diabetes .", "label": "", "metadata": {}, "score": "73.79016"}
{"text": "Medline ] 5 .Urakami T. Treatment for childhood type 2 diabetes .Clin Pediatr Endocrinol 2005;14:1 - 9 . [CrossRef ] 6 .Asayama K , Ozeki T , Sugihara S , Ito K , Okada T , Tamai H , et al .", "label": "", "metadata": {}, "score": "73.893036"}
{"text": "The optimal dosage of GLP-1 agonists for maintenance therapy in children with T2DM should be examined in further studies .In addition , the efficacy and safety of incretin- related drugs should be studied in a large pediatric population .", "label": "", "metadata": {}, "score": "74.12288"}
{"text": "View Article PubMed .Raz I , Hanefeld M , Xu L , Caria C , Williams - Herman D , Khatami H , Sitagliptin Study 023 Group : Efficacy and safety of the dipeptyl peptidase 4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "74.16266"}
{"text": "View Article PubMed .Raz I , Hanefeld M , Xu L , Caria C , Williams - Herman D , Khatami H , Sitagliptin Study 023 Group : Efficacy and safety of the dipeptyl peptidase 4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "74.16266"}
{"text": "Patients using basal - bolus insulin who are noncompliant with BG self - monitoring and titration of multiple insulin doses .To enable adequate titration of premixed insulin , the recommendation for BG self - monitoring is one measurement taken before each meal injection [ 14 , 20 ] .", "label": "", "metadata": {}, "score": "74.25562"}
{"text": "Insulin detemir Insulin glargine Type 2 diabetes Dose Health care costs .Background .Type 2 diabetes ( T2D ) is a chronic and potentially disabling disease that affects around 350 million people worldwide [ 1 ] .", "label": "", "metadata": {}, "score": "74.281296"}
{"text": "Conceptually , \" fix the fasting first \" is the initial agenda .This is accomplished most efficiently by the addition of basal insulin .Decreases in PPG excursions may also be achieved by lowering the overall glycemic profile with basal insulin ( Figure 1 ) .", "label": "", "metadata": {}, "score": "74.37839"}
{"text": "Data collection .Data was collected by a self - administered questionnaire to general practitioners ( GPs ) and specialists .The questionnaire included information on patient characteristics ( gender , age , weight , height , latest HbA 1c -value ) , use of insulin and non - insulin anti - diabetic medication .", "label": "", "metadata": {}, "score": "74.52957"}
{"text": "C.:-F .. 2,,,77 American Diabetes Association from Diabetes Care , Vol .30 , 2007 ; S4-S41 Modified with permission from The American Diabetes Association . sions becomes progressively impaired due to reduced endogenous insulin secretion resulting from loss of p - cell function [ 9,16].", "label": "", "metadata": {}, "score": "74.65843"}
{"text": "Parts of this study were presented in abstract form at the 68th Scientific Sessions of the American Diabetes Association , San Francisco , California , 6 - 10 June 2008 .", "label": "", "metadata": {}, "score": "74.69043"}
{"text": "Conclusions .This nonsystematic review provides a compilation of recent data comparing the efficacy and safety of premixed insulin analogues versus basal insulin analogues used alone or in combination with rapid - acting insulin analogues before meals in patients with T2DM .", "label": "", "metadata": {}, "score": "74.696754"}
{"text": "A total of 74 patients with DKA were randomly assigned in this study .Of them , six patients were excluded because four withdrew consent before or shortly after initiation of insulin therapy , one patient received glargine insulin before resolution of DKA , and one patient was treated with intravenous aspart insulin instead of regular insulin .", "label": "", "metadata": {}, "score": "74.69676"}
{"text": "Table 2 .Orally administered anti - diabetic drugs ( OAD ) and insulin at baseline and the end of the monitoring period .Efficacy of treatment .", "label": "", "metadata": {}, "score": "74.712715"}
{"text": "Table 2 .Orally administered anti - diabetic drugs ( OAD ) and insulin at baseline and the end of the monitoring period .Efficacy of treatment .", "label": "", "metadata": {}, "score": "74.712715"}
{"text": "First step : preprandial monitoring .When initiating treatment with premixed analogue insulin BID , it is recommended that patients measure BG just before breakfast and dinner as well as when there are symptoms consistent with hypoglycemia [ 13 ] .", "label": "", "metadata": {}, "score": "74.728455"}
{"text": "A limitation of this study is the sensitivity to selection bias as the participating GP offices and specialists were not selected randomly .However , the study population is large and diverse which makes it highly probable that the main conclusion of no significant dose differences between DET and GLAR in a once daily regime is representative for all T2D patients in Denmark .", "label": "", "metadata": {}, "score": "74.94656"}
{"text": "Below are the links to the authors ' original submitted files for images .Competing interests .Nicholas Tentolouris has received honoraria from NovoNordisk , Sanofi , Elli - Lilly , Bristol - Myers - Squibb and Novartis for memberships on advisory boards and for speaking on subjects related to treatment with antidiabetic drugs and insulin .", "label": "", "metadata": {}, "score": "75.06371"}
{"text": "Below are the links to the authors ' original submitted files for images .Competing interests .Nicholas Tentolouris has received honoraria from NovoNordisk , Sanofi , Elli - Lilly , Bristol - Myers - Squibb and Novartis for memberships on advisory boards and for speaking on subjects related to treatment with antidiabetic drugs and insulin .", "label": "", "metadata": {}, "score": "75.06371"}
{"text": "Patients can choose a different meal each day .Monitoring both premeal and 2-hour PPG may help identify problem meals undetected by premeal glucose monitoring alone .", "label": "", "metadata": {}, "score": "75.0725"}
{"text": "Patients should be given , on the prior evening , a predinner dose of split - mixed insulin ( NPH plus regular human insulin ) or a predinner dose of premixed insulin as usual .", "label": "", "metadata": {}, "score": "75.078766"}
{"text": "2005 , Brussels : IDF Communications , 39 - 42 .Monnier L , Lapinski H , Colette C : Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients : variations with increasing levels of HbA(1c ) .", "label": "", "metadata": {}, "score": "75.12975"}
{"text": "10.1016/S0140 - 6736(09)60697 - 8 .View Article PubMed .Gaede P , Lund - Andersen H , Parving HH , Pedersen O : Effect of a multifactorial intervention on mortality in type 2 diabetes .", "label": "", "metadata": {}, "score": "75.13847"}
{"text": "Lantus \u00ae is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or one of its excipients .Warnings and Precautions .Insulin pens , needles , or syringes must never be shared between patients .", "label": "", "metadata": {}, "score": "75.311386"}
{"text": "Lantus \u00ae is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or one of its excipients .Warnings and Precautions .Insulin pens , needles , or syringes must never be shared between patients .", "label": "", "metadata": {}, "score": "75.311386"}
{"text": "Monitor blood glucose in all patients treated with insulin .Modify insulin regimen cautiously and only under medical supervision .Changes in insulin strength , manufacturer , type , or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment .", "label": "", "metadata": {}, "score": "75.54498"}
{"text": "Monitor blood glucose in all patients treated with insulin .Modify insulin regimen cautiously and only under medical supervision .Changes in insulin strength , manufacturer , type , or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment .", "label": "", "metadata": {}, "score": "75.54498"}
{"text": "Diabetes Care 2005 , 28:1107 - 1I 112 .Publish with BioMed Central and every scientist can read your work free of charge \" BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime . \"", "label": "", "metadata": {}, "score": "75.61096"}
{"text": "Gerich JE : Clinical significance , pathogenesis , and manage- ment of postprandial hyperglycemia .Arch Intern Med 2003 , 163:1306 - 1316 .Monnier L : Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes ?", "label": "", "metadata": {}, "score": "75.80681"}
{"text": "In addition , active group had a significantly higher HbA1c and fasting BG when compared to control group ( Table 1 ) .Equal number of participants had been treated with metformin , sulfonylurea , meglitinides and alpha - glucosidase inhibitors in the control and the active group at baseline .", "label": "", "metadata": {}, "score": "75.87334"}
{"text": "In addition , active group had a significantly higher HbA1c and fasting BG when compared to control group ( Table 1 ) .Equal number of participants had been treated with metformin , sulfonylurea , meglitinides and alpha - glucosidase inhibitors in the control and the active group at baseline .", "label": "", "metadata": {}, "score": "75.87334"}
{"text": "If BID - Adjust morning insulin dose based on the average predinner blood glucose and evening insulin dose based on the average prebreakfast / fasting blood glucose .", "label": "", "metadata": {}, "score": "76.13079"}
{"text": "It is also recognized as being safe with a low risk of hypoglycemia and less weight gain than other SUs ( 13 ) .Glimepiride , but not glibenclamide , also has extrapancreatic effects that?might?protect?\u03b2 - cells?from?apoptosis?through , ? at least in part , the antioxidant properties of the molecule ( 14 ) .", "label": "", "metadata": {}, "score": "76.17995"}
{"text": "Rapid - acting insulin analogs have an onset of action within 15 minutes of administration , a peak effect within 0.5 - 1.5 hours , and a return to basal concentrations within 2 - 4 hours [ 13].", "label": "", "metadata": {}, "score": "76.19145"}
{"text": "The importance of good glycaemic control constitutes the cornerstone of every therapeutic modality in patients with diabetes .Prospective randomised studies have clearly shown that effective diabetes control , as judged by HbA1c , is associated with lower incidence of chronic complications , especially microangiopathy , both in patients with type 1 and type 2 diabetes [ 6 , 7 ] .", "label": "", "metadata": {}, "score": "76.26558"}
{"text": "The importance of good glycaemic control constitutes the cornerstone of every therapeutic modality in patients with diabetes .Prospective randomised studies have clearly shown that effective diabetes control , as judged by HbA1c , is associated with lower incidence of chronic complications , especially microangiopathy , both in patients with type 1 and type 2 diabetes [ 6 , 7 ] .", "label": "", "metadata": {}, "score": "76.26558"}
{"text": "Most obese patients , at the early stage of diabetes , achieve adequate glycemic control using metformin alone , with some subsequently needing additional medications?including?an?\u03b1 - GI , ?", "label": "", "metadata": {}, "score": "76.65084"}
{"text": "There was no mortality , and none of the patients had a recurrence of DKA during their hospital stay .To convert the values for glucose from milligrams per deciliter to millimoles per liter , multiply by 0.05551 .", "label": "", "metadata": {}, "score": "77.14487"}
{"text": "Both regimens were well tolerated .The risk for severe hypoglycemia was low and not significantly different between groups .Other studies ( 15 , 16 ) have shown that patients whose diabetes is well - controlled with insulin often have a basal : bolus insulin ratio close to 50%:50 % .", "label": "", "metadata": {}, "score": "77.33212"}
{"text": "Weight beneficial treatments for type 2 diabetes .L F Meneghini Diabetes Research Institute , University of Miami Miller School of Medicine , 1450 N W 10th Avenue , Miami , Florida 33136 , USA J Clin Endocrinol Metab 96:3337 - 53 .", "label": "", "metadata": {}, "score": "77.704796"}
{"text": "Weight beneficial treatments for type 2 diabetes .L F Meneghini Diabetes Research Institute , University of Miami Miller School of Medicine , 1450 N W 10th Avenue , Miami , Florida 33136 , USA J Clin Endocrinol Metab 96:3337 - 53 .", "label": "", "metadata": {}, "score": "77.704796"}
{"text": "10.1056/NEJMoa0806470 .View Article PubMed .Ray KK , Seshasai SR , Wijesuriya S , Sivakumaran R , Nethercott S , Preiss D , Erqou S , Sattar N : Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus : a meta - analysis of randomised controlled trials .", "label": "", "metadata": {}, "score": "77.70852"}
{"text": "American Diabetes Association : Standards of medical care in diabetes--2007 .Diabetes Core 2007 , 30(suppl I):S4-S41 .Stratton IM , Adler Al , Neil HA , Matthews DR , Manley SE , Cull CA , Hadden D , Turner RC , Holman RR : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes ( UKPDS 35 ) : prospective observational study .", "label": "", "metadata": {}, "score": "77.81763"}
{"text": "One hundred January 2013 Fig .1 Treatment decision according to the ISPAD guidelines 2009 .Page 6 .Urakami et al .6 and seventy - two patients ( 66 % ) were treated using?OHDs .", "label": "", "metadata": {}, "score": "77.944855"}
{"text": "Elevated A1C and postprandial glucose levels have been related to risk for long - term complications in diabetes ( 1 - 3 ) .Insulin therapy is often needed to achieve target A1C and postprandial glucose levels in type 2 diabetes ( 4 ) .", "label": "", "metadata": {}, "score": "78.15242"}
{"text": "DAFNE Study Group : Training in flexible , intensive insulin management to enable dietary freedom in people with type 1 diabetes : dose adjustment for normal eating ( DAFNE ) randomised controlled trial .", "label": "", "metadata": {}, "score": "78.313866"}
{"text": "10.1089/dia.2009.0091 .View Article PubMed .Hortensius J , Kleefstra N , Houweling ST , Van der Bijl JJ , Gans RO , Bilo HJG : What do professionals recommend regarding the frequency of self - monitoring of blood glucose ?", "label": "", "metadata": {}, "score": "78.52269"}
{"text": "Warnings and Precautions .Insulin pens , needles , or syringes must never be shared between patients .Do NOT reuse needles .Monitor blood glucose in all patients treated with insulin .", "label": "", "metadata": {}, "score": "78.56497"}
{"text": "Warnings and Precautions .Insulin pens , needles , or syringes must never be shared between patients .Do NOT reuse needles .Monitor blood glucose in all patients treated with insulin .", "label": "", "metadata": {}, "score": "78.56497"}
{"text": "; the LS mean ( 95 % CI)% change in body weight was -0.121 ( -0.754 , 0.511 ) kg .Daily insulin use .Similar changes were found in total daily insulin dose expressed in U / kg / day ( Table 2 ) .", "label": "", "metadata": {}, "score": "78.64446"}
{"text": "; the LS mean ( 95 % CI)% change in body weight was -0.121 ( -0.754 , 0.511 ) kg .Daily insulin use .Similar changes were found in total daily insulin dose expressed in U / kg / day ( Table 2 ) .", "label": "", "metadata": {}, "score": "78.64446"}
{"text": "Treatment Guidelines For patients with type 2 diabetes , A1C values ideally should be measured every 3 - 6 months .Adjust therapy when glycemic control is above the ADA target of 7.0 % ( Figure 2 ) [ 3].", "label": "", "metadata": {}, "score": "78.69593"}
{"text": "Certain drugs may affect glucose metabolism , requiring insulin dose adjustment and close monitoring of blood glucose .The signs of hypoglycemia may be reduced in patients taking anti - adrenergic drugs ( e.g. , beta - blockers , clonidine , guanethidine , and reserpine ) .", "label": "", "metadata": {}, "score": "78.8748"}
{"text": "Certain drugs may affect glucose metabolism , requiring insulin dose adjustment and close monitoring of blood glucose .The signs of hypoglycemia may be reduced in patients taking anti - adrenergic drugs ( e.g. , beta - blockers , clonidine , guanethidine , and reserpine ) .", "label": "", "metadata": {}, "score": "78.8748"}
{"text": "Certain drugs may affect glucose metabolism , requiring insulin dose adjustment and close monitoring of blood glucose .The signs of hypoglycemia may be reduced in patients taking anti - adrenergic drugs ( e.g. , beta - blockers , clonidine , guanethidine , and reserpine ) .", "label": "", "metadata": {}, "score": "78.8748"}
{"text": "Certain drugs may affect glucose metabolism , requiring insulin dose adjustment and close monitoring of blood glucose .The signs of hypoglycemia may be reduced in patients taking anti - adrenergic drugs ( e.g. , beta - blockers , clonidine , guanethidine , and reserpine ) .", "label": "", "metadata": {}, "score": "78.8748"}
{"text": "References 1 .Bloomgarden ZT .Type 2 diabetes in the young .The evolving epidemic .Diabetes Care 2004;27:998 - 1010 .[Medline ] [ CrossRef ] 2 .", "label": "", "metadata": {}, "score": "78.93179"}
{"text": "Monnier L , Lapinski H , Colette C : Contributions of fasting and postprandial plasma glucose increments to the overall diur- nal hyperglycemia of type 2 diabetic patients : variations with increasing levels of HbAlc .", "label": "", "metadata": {}, "score": "79.03809"}
{"text": "Concomitant treatment with OAD .No other significant change in the use of other OAD was noticed during the follow up period ( Table 2 ) .", "label": "", "metadata": {}, "score": "79.267715"}
{"text": "Concomitant treatment with OAD .No other significant change in the use of other OAD was noticed during the follow up period ( Table 2 ) .", "label": "", "metadata": {}, "score": "79.267715"}
{"text": "ME : Endocrinologist , MD .During the preparation of this manuscript , ME was a Diabetes Regional Medical Advisor for Emerging Markets at Eli Lilly .", "label": "", "metadata": {}, "score": "79.38049"}
{"text": "For the obese patients , decreased appetite and slower gastric emptying leading to weight loss , which was modest in some patients but significant in others , was the main advantage of GLP-1 Vol.22 / No.1 .", "label": "", "metadata": {}, "score": "79.425316"}
{"text": "Dose comparisons were strictly performed for the same treatment algorithm ( once daily dosing of DET or GLAR ) in accordance with the aim of the study ( as it otherwise would include off - label use of GLAR ) .", "label": "", "metadata": {}, "score": "79.52725"}
{"text": "Pharmacologic therapies were started if the HbA1c ( NGSP ) value exceeded 7.0 % despite dietary and exercise management .For the 26 obese patients , metformin alone or in combination with an additional medication was frequently used .", "label": "", "metadata": {}, "score": "79.633896"}
{"text": "The higher rate of hypoglycemia with human insulins is explained by the pharmacological features and peak duration of action of NPH and regular insulin ( 10 ) as well as the high day - to - day variability in absorption ( 11 ) .", "label": "", "metadata": {}, "score": "79.68271"}
{"text": "However , premixed analogues tend to cause a small increase in the risk of nonsevere hypoglycemic events and a small , not clinically significant weight gain [ 13 - 19 ] .", "label": "", "metadata": {}, "score": "80.01477"}
{"text": "Coutinho M , Gerstein HC , Wang Y , Yusuf S : The relationship between glucose and incident cardiovascular events : a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years .", "label": "", "metadata": {}, "score": "80.15515"}
{"text": "Group : Effect of intensive blood glucose control with metformin on complication in overwight patients with type 2 diabetes ( UKPDS 34 ) .Lancet .", "label": "", "metadata": {}, "score": "80.339386"}
{"text": "Group : Effect of intensive blood glucose control with metformin on complication in overwight patients with type 2 diabetes ( UKPDS 34 ) .Lancet .", "label": "", "metadata": {}, "score": "80.339386"}
{"text": "Titration of insulin before breakfast is based on BG before dinner , and titration before dinner is based on BG before breakfast , as described in Table 3 .", "label": "", "metadata": {}, "score": "80.42781"}
{"text": "Lifestyle ?( diet?and?activity ) ?modifications?in?the?entire?family .Dietary?management . a )Limiting of high - fat , high - caloric density foods and drinks .", "label": "", "metadata": {}, "score": "80.482254"}
{"text": "In that context , patients ' clinical and psychosocial characteristics are key factors in the modification of the glycemic targets .Riddle [ 37 ] recently commented on the clinical implications stemming from the ACCORD trial results .", "label": "", "metadata": {}, "score": "80.4914"}
{"text": "Although basal - bolus insulin therapy can improve glycemic control in type 1 ( 6 , 18 ) and type 2 ( 19 , 20 ) diabetes , the most effective use of SMBG for adjusting the basal - bolus insulin doses has not been clearly established ( 21 - 24 ) .", "label": "", "metadata": {}, "score": "80.56823"}
{"text": "View Article PubMed .The action to control cardiovascular risk in diabetes study group : Effects of intensive lowering in type 2 diabetes .N Engl J Med .", "label": "", "metadata": {}, "score": "80.569374"}
{"text": "View Article PubMed .The action to control cardiovascular risk in diabetes study group : Effects of intensive lowering in type 2 diabetes .N Engl J Med .", "label": "", "metadata": {}, "score": "80.569374"}
{"text": "Diabetes 2006 , 55 supplyl I):A 135 .Rohlfing CL , Wiedmeyer HM , Little RR , England JD , Tennill A , Gold- stein DE : Defining the relationship between plasma glucose and HbAlc : analysis of glucose profiles and HbAlc in the .", "label": "", "metadata": {}, "score": "80.59004"}
{"text": "All the patients were initially treated with a monotherapy of metformin or other OHD ; i.e. , 16 were treated with metformin , 4 were treated with sulfonylurea ( SU ) and 2 were treated with an?\u03b1 - glucosidase?inhibitor ?", "label": "", "metadata": {}, "score": "80.62094"}
{"text": "View Article .Diabetes control and complications trial research group : The effect of intensive diabetes treatment on the development and progression of long term complications in insulin - dependent diabetes mellitus : the diabetes control and complications trial .", "label": "", "metadata": {}, "score": "80.81115"}
{"text": "View Article .Diabetes control and complications trial research group : The effect of intensive diabetes treatment on the development and progression of long term complications in insulin - dependent diabetes mellitus : the diabetes control and complications trial .", "label": "", "metadata": {}, "score": "80.81115"}
{"text": "2012 , S89-S90 .55(Suppl 1 ) .Riddle M , Umpierrez G , DiGenio A , Zhou R , Rosenstock J : Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes .", "label": "", "metadata": {}, "score": "81.042984"}
{"text": "10.4158/EP.15.6.540 .View Article .Jacob AN , Salinas K , Adams - Huet B , Raskin P : Weight gain in type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "81.0812"}
{"text": "10.1056/NEJM198402093100602 .View Article PubMed .Diabetes Res Clin Pract .10.1016/0168 - 8227(95)01064-K. View Article PubMed .Stratton IM , Adler AI , Neil HA , Matthews DR , Manley SE , Cull CA , Hadden D , Turner RC , Holman RR : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes ( UKPDS 35 ) : prospective observational study .", "label": "", "metadata": {}, "score": "81.134"}
{"text": "These results suggest that pharmacologic treatment strategies in childhood T2DM should be tailored to individual patient characteristics .Full - text .We treated 80 obese and 28 nonobese children diagnosed as having type 2 diabetes mellitus ( T2DM ) .", "label": "", "metadata": {}, "score": "81.17873"}
{"text": "Diabetes Metab Res Rev 2007;23:234 - 8 .[Medline ] [ CrossRef ] ?Amori?RE , ? Lau?J , ? Pittas?AG .Efficacy?and?safety ?January 2013 .", "label": "", "metadata": {}, "score": "81.34659"}
{"text": "DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes : a randomized open - label , non - inferiority study .", "label": "", "metadata": {}, "score": "81.46994"}
{"text": "Diabetes Control and Complications Trial Research Group :The effect of intensive treatment of diabetes on the development and progression of the long - term complications of insulin - dependent diabetes mellitus .", "label": "", "metadata": {}, "score": "81.61044"}
{"text": "RESULTS .The clinical characteristics of study patients on admission are shown in Table 1 .The mean age , duration of diabetes , and precipitating cause for DKA were similar between treatment groups .", "label": "", "metadata": {}, "score": "81.614716"}
{"text": "10.2337/dc09 - 0097 .PubMed Central View Article PubMed .Poolsup N , Suksomboon N , Rattanasookchit S : Meta - analysis of the benefits of self - monitoring of blood glucose on glycemic control in type 2 diabetes patients : an update .", "label": "", "metadata": {}, "score": "81.64803"}
{"text": "A DPP4 inhibitor and GLP-1 receptor agonist alone or in addition to metformin exerted positive effects on glycemic control without inducing hypoglycemic episodes?in?the ? patients?with?residual?\u03b2 - cell ? function within a relatively short period after the diagnosis ( Table 3 ) .", "label": "", "metadata": {}, "score": "81.70701"}
{"text": "Hypoglycemia is the most common adverse reaction of insulin therapy , including Lantus \u00ae , and may be life - threatening .Medication errors , such as accidental mix - ups between basal insulin products and other insulins , particularly rapid - acting insulins , have been reported .", "label": "", "metadata": {}, "score": "81.76084"}
{"text": "Hypoglycemia is the most common adverse reaction of insulin therapy , including Lantus \u00ae , and may be life - threatening .Medication errors , such as accidental mix - ups between basal insulin products and other insulins , particularly rapid - acting insulins , have been reported .", "label": "", "metadata": {}, "score": "81.76084"}
{"text": "Hypoglycemia is the most common adverse reaction of insulin therapy , including Lantus \u00ae , and may be life - threatening .Medication errors , such as accidental mix - ups between basal insulin products and other insulins , particularly rapid - acting insulins , have been reported .", "label": "", "metadata": {}, "score": "81.76084"}
{"text": "Hypoglycemia is the most common adverse reaction of insulin therapy , including Lantus \u00ae , and may be life - threatening .Medication errors , such as accidental mix - ups between basal insulin products and other insulins , particularly rapid - acting insulins , have been reported .", "label": "", "metadata": {}, "score": "81.76084"}
{"text": "Minimizing the rate of hypoglycemia events is of major importance in hospitalized patients because it may represent an independent risk factor of poor clinical outcome ( 24 ) .", "label": "", "metadata": {}, "score": "82.03949"}
{"text": "S.J. has received honoraria for serving on the speaker 's bureau and a research grant from sanofi - aventis .D.S. has received honoraria for serving on the speaker 's bureau and a research grant from sanofi - aventis .", "label": "", "metadata": {}, "score": "82.158455"}
{"text": "The recently published ADA and EASD [ 8 ] position statement also reinforces this strategy as a good practice when dealing with T2DM in naturalistic clinical practice as part of individualizing therapy for the patient .", "label": "", "metadata": {}, "score": "82.323425"}
{"text": "10.1111/j.1464 - 5491.2007.02129.x .View Article PubMed .Yu CH , Parsons J , Mamdani M , Lebovic G , Shah BR , Bhattacharyya O , Laupacis A , Straus SE : Designing and evaluating a web - based self - management site for patients with type 2 diabetes - systematic website development and study protocol .", "label": "", "metadata": {}, "score": "82.32695"}
{"text": "The materials for the simple algorithm group omitted all references to carbohydrate intake except in the context of treating hypoglycemia and having carbohydrate if alcohol was being consumed .", "label": "", "metadata": {}, "score": "82.52496"}
{"text": "If A1C is not within the desired range , BG is measured before dinner for a few days .If the values are high , premixed insulin analogues can be initiated before breakfast [ 10 ] .", "label": "", "metadata": {}, "score": "82.55493"}
{"text": "Voiceover : All known insulins are composed of two polypeptide chains that are linked to one another by disulfide bonds .Lantus \u00ae differs from human insulin in that the physiochemical properties have been modified .", "label": "", "metadata": {}, "score": "82.73734"}
{"text": "Conclusions .Based on this study , we conclude that the real - life daily doses of DET and GLAR in Danish T2D patients are similar when administered once daily .", "label": "", "metadata": {}, "score": "82.783264"}
{"text": "These findings suggest that if lowering FBG is the treatment goal ( basal insulin ) , then FBG would contribute to approximately 34 % of A1C ( mean value 7.7 % ) and postprandial BG to approximately 66 % of A1C. If lowering postprandial BG is the treatment goal ( intensifying insulin treatment with premixed insulin or adding prandial insulin ) , then FBG would contribute to approximately 68 % of A1C ( mean 7.7 % ) and 32 % of postprandial BG [ 33 ] .", "label": "", "metadata": {}, "score": "82.95207"}
{"text": "Forty - nine of these patients , 13 males and 36 females , with a mean age of 23.0 \u00b1 5.8 yr , and a mean duration of diabetes of 12.5 \u00b1 3.5 yr , were given pharmacologic therapies during the course of diabetes management .", "label": "", "metadata": {}, "score": "82.98822"}
{"text": "The ADVANCE Collaborative Group : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes .N Engl J Med .View Article .", "label": "", "metadata": {}, "score": "83.1219"}
{"text": "The ADVANCE Collaborative Group : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes .N Engl J Med .View Article .", "label": "", "metadata": {}, "score": "83.1219"}
{"text": "Luigi Meneghini University of Miami Miller School of Medicine , Miami , Florida , USA Diabetes Care 36:858 - 64 .Impact of bariatric surgery on type 2 diabetes .", "label": "", "metadata": {}, "score": "83.45542"}
{"text": "10.1111/j.1463 - 1326.2005.00563.x .View Article PubMed .Sociedade Brasileira de Diabetes : Algoritmo para o tratamento do Diabetes Tipo 2 - Atualiza\u00e7\u00e3o .", "label": "", "metadata": {}, "score": "83.592964"}
{"text": "Symptomatic hypoglycemia was also documented .Data analysis .Populations .Sample size .The noninferiority hypothesis was to be tested ; a study with 86 evaluable subjects per treatment arm would have 90 % power to detect treatment differences of 0.5 % .", "label": "", "metadata": {}, "score": "83.61179"}
{"text": "Key words : type 2 diabetes , obese , nonobese , pharmacologic therapies Introduction Treatment of childhood type 2 diabetes mellitus ( T2DM ) is a critical issue because the number of children with T2DM has dramatically increased worldwide in recent decades ( 1 , 2 ) .", "label": "", "metadata": {}, "score": "83.84453"}
{"text": "Acknowledgments .Editorial support was provided through the sanofi - aventis US Group .Footnotes .R.M.B. receives grant funds from , serves on an advisory panel for , and is a consultant for sanofi - aventis .", "label": "", "metadata": {}, "score": "83.8463"}
{"text": "2Adding Lantus \u00ae to an oral regimen has been shown to be effective at improving and sustaining glycemic control .The clinical efficacy of Lantus \u00ae has been evaluated in patients with type 1 and type 2 diabetes mellitus in several large , randomized , multicenter trials .", "label": "", "metadata": {}, "score": "83.88122"}
{"text": "However , recent studies have found that intensive treatment does not lead to a reduction in new CVD or reduced mortality in patients with a prior history of CVD [ 34 , 35 ] .", "label": "", "metadata": {}, "score": "83.90802"}
{"text": "References I. Centers for Disease Control and Prevention : National diabetes fact sheet : United States , 2005 : general information . pdf].American Association of Clinical Endocrinologists : The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus : the AACE system of intensive diabetes self - management-2002 update .", "label": "", "metadata": {}, "score": "84.0233"}
{"text": "A key concept in the treatment of T2DM is establishing individualized glycemic goals [ 9 ] .Targets for glycemic control , including fasting BG ( FBG ) , postprandial BG , and A1C as well as lipid and blood pressure levels , should be identified by the physician and the patient and ultimately achieved by therapeutic means .", "label": "", "metadata": {}, "score": "84.183624"}
{"text": "These patients should be observed for signs and symptoms of heart failure .If heart failure occurs , dosage reduction or discontinuation of TZD must be considered .", "label": "", "metadata": {}, "score": "84.25814"}
{"text": "These patients should be observed for signs and symptoms of heart failure .If heart failure occurs , dosage reduction or discontinuation of TZD must be considered .", "label": "", "metadata": {}, "score": "84.25814"}
{"text": "These patients should be observed for signs and symptoms of heart failure .If heart failure occurs , dosage reduction or discontinuation of TZD must be considered .", "label": "", "metadata": {}, "score": "84.25814"}
{"text": "These patients should be observed for signs and symptoms of heart failure .If heart failure occurs , dosage reduction or discontinuation of TZD must be considered .", "label": "", "metadata": {}, "score": "84.25814"}
{"text": "An estimated 90%- 95 % of cases are type 2 diabetes [ 2].Despite abundant evidence regarding the increased risk of serious micro- and macrovascular complications associated with poor glycemic control , only a small proportion of patients with type 2 diabetes attain the recommended treatment goals ( Table 1 ) .", "label": "", "metadata": {}, "score": "84.26579"}
{"text": "View Article PubMed .Riddle MC : Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes ( ACCORD ) trial .", "label": "", "metadata": {}, "score": "84.321884"}
{"text": "The evidence from clinical trials comparing DET and GLAR is inconsistent in terms of dose - related findings .This study is consistent with the results of a clinical trial including 385 American T2D patients in a basal - bolus regimen , which did not find significant dose differences between DET and GLAR [ 14 ] .", "label": "", "metadata": {}, "score": "84.38443"}
{"text": "View Article PubMed .Wajchenberg BL : beta - cell failure in diabetes and preservation by clinical treatment .Endocr Rev. 2007 , 28 : 187 - 218 .", "label": "", "metadata": {}, "score": "84.40625"}
{"text": "At the end of the study there was a significant reduction in HbA1c in both arms .Similarly , fasting blood glucose declined significantly in both arms .", "label": "", "metadata": {}, "score": "84.74136"}
{"text": "At the end of the study there was a significant reduction in HbA1c in both arms .Similarly , fasting blood glucose declined significantly in both arms .", "label": "", "metadata": {}, "score": "84.74136"}
{"text": "Excessive restriction of food intake impairs physical development in childhood and is likely to lead to patient withdrawal from the regimen over time ( 3 , 4 ) .", "label": "", "metadata": {}, "score": "84.76106"}
{"text": "Keywords .Type 2 diabetes mellitus Insulin Premixed Lispro Glycated hemoglobin Treatment goals Titration .Introduction .In 2011 , the prevalence of diabetes mellitus worldwide was approximately 366 million people [ 1 ] .", "label": "", "metadata": {}, "score": "84.99179"}
{"text": "Hence , to define whether PPG immedi- ately postmeal is the culprit responsible for inadequate control , they should be instructed to specifically monitor 2-hour PPG levels [ 39].", "label": "", "metadata": {}, "score": "85.11075"}
{"text": "Ismail - Beigi F , Moghissi E , Tiktin M , Hirsch IB , Inzucchi SE , Genuth S : Individualizing glycemic targets in type 2 diabetes mellitus : implications of recent clinical trials .", "label": "", "metadata": {}, "score": "85.12633"}
{"text": "The study was approved by hospitals research ethics committees and by National Organization for Medicines .Patients ' selection by investigators and inclusion in the study was taking place consecutively , starting from most recent patient 's data ( from each patient 's last visit ) and going backwards in time .", "label": "", "metadata": {}, "score": "85.31182"}
{"text": "The study was approved by hospitals research ethics committees and by National Organization for Medicines .Patients ' selection by investigators and inclusion in the study was taking place consecutively , starting from most recent patient 's data ( from each patient 's last visit ) and going backwards in time .", "label": "", "metadata": {}, "score": "85.31182"}
{"text": "In addition , we used repeated - measures linear models to examine the group differences while adjusting for subject 's age , sex , race , and BMI .", "label": "", "metadata": {}, "score": "85.33687"}
{"text": "10.1016/j.clinthera.2004.12.015 .View Article PubMed .Roach P , Arora V , Campaigne BN , Mattoo V , Rangwala S : Humalog Mix50 before carbohydrate - rich meals in type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "85.41374"}
{"text": "Authors ' information .MT : Head of the discipline of endocrinology , School of Medical Sciences , Universidade Estadual de Campinas .MN : Endocrinologist , MD , Supervisor of The Medical Service of Endocrinology and Metabolism and Head of the Diabetes Unit of the School of Medicine Universidade de S\u00e3o Paulo .", "label": "", "metadata": {}, "score": "85.463066"}
{"text": "Cryer PE , Davis SN , Shamoon H : Hypoglycemia in diabetes .Dio- betes Care 2003 , 26:1902 - 1912 .Diabetes Care 2006 , 29:1269 - 1274 . html].", "label": "", "metadata": {}, "score": "85.477646"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations .Diabetes Unit - Endocrinology and Metabolism Service , Clinical Hospital of Faculty of Medicine , University of S\u00e3o Paulo .", "label": "", "metadata": {}, "score": "85.650604"}
{"text": "The nonobese patients were basically negative for any diabetes - related autoantibodies .Thus , genetic factors not associated with autoimmunity may play a role in?the?deterioration?of?\u03b2 - cell?function?in?nonobese ? children with T2DM ( unpublished data ) .", "label": "", "metadata": {}, "score": "85.67804"}
{"text": "The GPs were asked to fill in a questionnaire for each of their T2D patients treated with either DET or GLAR based on information registered in their computer system .", "label": "", "metadata": {}, "score": "86.281265"}
{"text": "Blood glucose levels may need to be monitored more frequently in these patients over a short period of time , ideally 4 times per day for at least 2 weeks .", "label": "", "metadata": {}, "score": "86.458725"}
{"text": "Changes in blood glucose and acid - base parameters during treatment are shown in Fig . 1 .As suggested by the repeated - measures analyses , the rate of decline of blood glucose concentration and changes in acid base parameters during treatment were not significantly different between treatment groups with adjustment for age , sex , race , and BMI ( NS ) .", "label": "", "metadata": {}, "score": "86.52136"}
{"text": "L Meneghini Division of Endocrinology , Diabetes and Metabolism , University of Miami Miller School of Medicine , Miami , FL , USA Diabetes Obes Metab 15:729 - 36 .", "label": "", "metadata": {}, "score": "86.60889"}
{"text": "Of these children , 101 ( 93.5 % ) were diagnosed as having T2DM by urine glucose screening at schools .All the patients with T2DM were negative for any diabetes - related autoantibodies including islet cell antibodies ( ICA ) and anti - glutamic acid decarboxylase ( GAD ) antibodies at the time of diagnosis and during the course of the disease .", "label": "", "metadata": {}, "score": "86.728226"}
{"text": "The specialists were asked to fill in a questionnaire for each of their T2D patients treated with DET or GLAR whom they were in contact with from 29 November to 10 December 2010 .", "label": "", "metadata": {}, "score": "86.76285"}
{"text": "Department of Internal Medicine , General Hospital of Ioannina Chatzikosta . sanofi - aventis .References .Diabetes Care . 10.2337/dc08 - 9025 .", "label": "", "metadata": {}, "score": "86.78239"}
{"text": "Department of Internal Medicine , General Hospital of Ioannina Chatzikosta . sanofi - aventis .References .Diabetes Care . 10.2337/dc08 - 9025 .", "label": "", "metadata": {}, "score": "86.78239"}
{"text": "American Association of Clinical Endocrinologists / American College of Endocrinology : The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus : the AACE system of intensive diabetes self - management-2002 update .", "label": "", "metadata": {}, "score": "86.83024"}
{"text": "Both studies found that the mean daily dose of DET was higher than the mean daily dose of GLAR .However , these differences were mainly due to differences in treatment algorithms with more DET patients on twice daily dosing compared to GLAR patients .", "label": "", "metadata": {}, "score": "86.94666"}
{"text": "PubMed .Choudhary P : Review of dietary recommendations for diabetes mellitus .Diabetes Res Clin Pract .2004 , 65 ( Suppl 1 ) : S9-S15 .", "label": "", "metadata": {}, "score": "87.149216"}
{"text": "This will enhance the clinician 's ability to assess the patient 's progress and make timely dose adjustments .Importantly , patients will be more informed participants in their own care .", "label": "", "metadata": {}, "score": "87.18093"}
{"text": "Clin Pediatr Endocrinol 2005;14:65 - 75 . [CrossRef ] 10 .Ogihara T , Mirmira RG .2010 An islet in distress : \u03b2?cell?failure?in?type ? diabetes .", "label": "", "metadata": {}, "score": "87.28299"}
{"text": "Pediatr Diabetes 2007;8:7- 15 .[Medline ] [CrossRef ] 3 .Rosenbloom AL , Silverstein JH , Amemiya S , Zeiter P , Klingensmith GJ .", "label": "", "metadata": {}, "score": "87.44725"}
{"text": "Allowing for 15 % loss to follow - up , we recruited a total of 74 patients with DKA , of which 34 patients per group completed the study .", "label": "", "metadata": {}, "score": "87.45025"}
{"text": "The baseline A1C in patients with T2DM guides the physician in establishing the initial therapeutic approach and is also used as a reference for adjusting the therapy thereafter .", "label": "", "metadata": {}, "score": "87.51335"}
{"text": "Ethnic disparities in diabetes care : myth or reality ?Luigi Meneghini Diabetes Research Institute , University of Miami Leonard M Miller School of Medicine , Miami , Florida 33136 , USA Curr Opin Endocrinol Diabetes Obes 15:128 - 34 .", "label": "", "metadata": {}, "score": "87.69797"}
{"text": "Thus , routine check - ups are recommended twice a year for patients meeting treatment goals and quarterly ( every 3 months ) for all patients with T2DM whose therapy has been recently modified or who are not meeting their glycemic goals [ 7 , 10 , 11 , 30 ] .", "label": "", "metadata": {}, "score": "88.082794"}
{"text": "The Avandia debacle : methodology and practical importance of the findings .Luigi Fernando Meneghini Department of Medicine , University of Miami Miller School of Medicine , Miami , Florida , USA South Med J 100:1062 - 3 .", "label": "", "metadata": {}, "score": "88.12973"}
{"text": "This finding suggests that patients required a higher insulin dose or needed to be switched to a more intensive treatment .Table 1 .Values of mean , fasting , and postprandial blood glucose ( BG ) corresponding to glycated hemoglobin ( A1C ) [ 31 ] .", "label": "", "metadata": {}, "score": "88.183754"}
{"text": "In particular , HbA1c declined by 1.13 % in the active and by 0.59 % in the control group and fasting BG declined by 47 mg / dl in the active and 20 mg / dl in the control group .", "label": "", "metadata": {}, "score": "88.34772"}
{"text": "In particular , HbA1c declined by 1.13 % in the active and by 0.59 % in the control group and fasting BG declined by 47 mg / dl in the active and 20 mg / dl in the control group .", "label": "", "metadata": {}, "score": "88.34772"}
{"text": "Diabet?Invest ?Campbell RK .Glimepiride : role of a new sulfonylurea in the treatment of type 2 diabetes mellitus .Ann Pharmacother 1998;32:1044 - 52 .", "label": "", "metadata": {}, "score": "88.51384"}
{"text": "Adverse events caused six ( 4.3 % ) patients in the carb count group and three ( 2.2 % ) patients in the simple algorithm group to discontinue treatment .", "label": "", "metadata": {}, "score": "88.51836"}
{"text": "Riddle concluded that , based on the ACCORD study results , glycemic targets should be individualized and current therapies adapted to each patient 's needs .", "label": "", "metadata": {}, "score": "89.02945"}
{"text": "If mixed or diluted , the solution may become cloudy , and the onset of action / time to peak effect may be altered in an unpredictable manner .", "label": "", "metadata": {}, "score": "89.09012"}
{"text": "If mixed or diluted , the solution may become cloudy , and the onset of action / time to peak effect may be altered in an unpredictable manner .", "label": "", "metadata": {}, "score": "89.09012"}
{"text": "If mixed or diluted , the solution may become cloudy , and the onset of action / time to peak effect may be altered in an unpredictable manner .", "label": "", "metadata": {}, "score": "89.09012"}
{"text": "If mixed or diluted , the solution may become cloudy , and the onset of action / time to peak effect may be altered in an unpredictable manner .", "label": "", "metadata": {}, "score": "89.09012"}
{"text": "10.1111/j.1464 - 5491.2005.01475.x .View Article PubMed .Skinner TC , Barnard K , Cradock S , Parkin T : Patient and professional accuracy of recalled treatment decisions in out - patient consultations .", "label": "", "metadata": {}, "score": "89.12564"}
{"text": "Brazil is expected to have 19.6 million patients with diabetes by the year 2030 .A key concept in the treatment of type 2 diabetes mellitus ( T2DM ) is establishing individualized glycemic goals based on each patient 's clinical characteristics , which impact the choice of antihyperglycemic therapy .", "label": "", "metadata": {}, "score": "89.39517"}
{"text": "Glargine was given once daily at the same time of day and glulisine was given in three equally divided doses before each meal .Glargine was given at the full dose independently of food intake , but to prevent hypoglycemia , the dose of glulisine was held if a subject was not able to eat a given meal .", "label": "", "metadata": {}, "score": "89.47516"}
{"text": "Figure I 24-hour glucose profiles for representative patients at different levels of glycemic control .Increasing A IC values reflect an elevated fasting or preprandial ( basal ) blood glucose level and elevated PPG excursions .", "label": "", "metadata": {}, "score": "89.53105"}
{"text": "L Meneghini Department of Medicine , University of Miami Miller School of Medicine , Miami , FL , USA Diabetes Obes Metab 9:902 - 13 .", "label": "", "metadata": {}, "score": "89.55226"}
{"text": "Pharmacotherapies for diabetes management : an update for the practicing clinician .Luigi Meneghini University of Miami Miller School of Medicine , Diabetes Research Institute , Miami , Florida 33136 , USA Semin Thorac Cardiovasc Surg 18:379 - 89 .", "label": "", "metadata": {}, "score": "89.61598"}
{"text": "However , it does not seem likely that there are differences between DET and GLAR patients with regard to compliance , and therefore this should not influence the main conclusion of no significant dose differences between DET and GLAR .", "label": "", "metadata": {}, "score": "89.65095"}
{"text": "Luigi F Meneghini Division of Endocrinology , Diabetes and Metabolism , Diabetes Research Institute , University of Miami Miller School of Medicine , Miami , Florida , USA Diabetes Care 31:1983 - 4 .", "label": "", "metadata": {}, "score": "89.703125"}
{"text": "The study showed that patients allocated in the basal - bolus regimen had superior glycaemic control vs. those allocated in the premix therapy with no increase in the rates of hypoglycaemia [ 21 ] .", "label": "", "metadata": {}, "score": "89.783295"}
{"text": "The study showed that patients allocated in the basal - bolus regimen had superior glycaemic control vs. those allocated in the premix therapy with no increase in the rates of hypoglycaemia [ 21 ] .", "label": "", "metadata": {}, "score": "89.783295"}
{"text": "Nabhan F , Emanuele MA , Emanuele N : Latent autoimmune diabe- tes of adulthood : unique features that distinguish it from types I and 2 .", "label": "", "metadata": {}, "score": "90.007484"}
{"text": "Blood glucose values at each visit declined in both arms , and the within - group change from baseline was statistically significant over all daily time points and study visits ( Fig .", "label": "", "metadata": {}, "score": "90.2086"}
{"text": "c ) Composition of food : C 53 - 57 % , P 15 - 17 % , F 30 % .Exercise?management .Negotiated and enjoyable exercise prescription to exhaust 5 - 10 % of daily caloric intake .", "label": "", "metadata": {}, "score": "90.32529"}
{"text": "However , because insurance companies often do not pay for more than 2 - 3 test strips per day , the following recommenda- tions have been developed as a best practice minimum .", "label": "", "metadata": {}, "score": "90.52836"}
{"text": "Lantus \u00ae SoloSTAR \u00ae is a disposable prefilled insulin pen .To help ensure an accurate dose each time , patients should follow all steps in the Instruction Leaflet accompanying the pen : otherwise they may not get the correct amount of insulin , which may affect their blood glucose .", "label": "", "metadata": {}, "score": "90.553116"}
{"text": "Lantus \u00ae SoloSTAR \u00ae is a disposable prefilled insulin pen .To help ensure an accurate dose each time , patients should follow all steps in the Instruction Leaflet accompanying the pen : otherwise they may not get the correct amount of insulin , which may affect their blood glucose .", "label": "", "metadata": {}, "score": "90.553116"}
{"text": "Lantus \u00ae SoloSTAR \u00ae is a disposable prefilled insulin pen .To help ensure an accurate dose each time , patients should follow all steps in the Instruction Leaflet accompanying the pen : otherwise they may not get the correct amount of insulin , which may affect their blood glucose .", "label": "", "metadata": {}, "score": "90.553116"}
{"text": "Lantus \u00ae SoloSTAR \u00ae is a disposable prefilled insulin pen .To help ensure an accurate dose each time , patients should follow all steps in the Instruction Leaflet accompanying the pen : otherwise they may not get the correct amount of insulin , which may affect their blood glucose .", "label": "", "metadata": {}, "score": "90.553116"}
{"text": "There is also a growing body of evidence indicating that postprandial hyperglycemia independently contributes to an increased risk for macrovascular complications [ 4,5,15,16,18 - 21].", "label": "", "metadata": {}, "score": "90.57208"}
{"text": "Diabetologia .10.1007/s00125 - 008 - 1157-y .View Article PubMed .Massi - Benedetti M , Orsini - Federici M : Treatment of type 2 diabetes with combined therapy : what are the pros and cons ?", "label": "", "metadata": {}, "score": "90.9422"}
{"text": "Diabetologia .10.1007/s00125 - 008 - 1157-y .View Article PubMed .Massi - Benedetti M , Orsini - Federici M : Treatment of type 2 diabetes with combined therapy : what are the pros and cons ?", "label": "", "metadata": {}, "score": "90.9422"}
{"text": "We also excluded patients with hypovolemic shock , patients in a comatose state , and patients who had acute myocardial ischemia , congestive heart failure , end - stage renal or hepatic failure , or pregnancy .", "label": "", "metadata": {}, "score": "91.3339"}
{"text": "P.H. receives grant funds from and serves on the speakers bureau and advisory panel for sanofi - aventis .The costs of publication of this article were defrayed in part by the payment of page charges .", "label": "", "metadata": {}, "score": "91.49551"}
{"text": "Luigi F Meneghini University of Miami Miller School of Medicine , Eleanor and Joseph Kosow Diabetes Treatment Center , Diabetes Research Institute , Miami , Florida 33136 , USA Endocr Pract 16:588 - 99 .", "label": "", "metadata": {}, "score": "91.9092"}
{"text": "Initially , elevated baseline FPG levels lead to a higher overall plasma glucose profile and conse- quently higher PPG excursions [ 16,22].Also , the relative contribution of FPG to A1C progressively increases as gly- cemic control worsens [ 16,22].", "label": "", "metadata": {}, "score": "92.20222"}
{"text": "If A1C is not below the pre - established goals at 4 months after insulin initiation , despite appropriate preprandial BG , then postprandial BG should be assessed .", "label": "", "metadata": {}, "score": "92.28314"}
{"text": "Diabetologia 2007;50:1900 - 9 . [CrossRef ] 19 .Inzucchi SE , Bergenstal RM , Buse JB , Diamant M , Ferrannini E , Nauck M , et al .", "label": "", "metadata": {}, "score": "92.79744"}
{"text": "[ 31 ] suggests that postprandial BG is the main contributor to the metabolic disequilibrium in those patients with mild or moderate hyperglycemia .Table 1 presents suggested values for FBG and postprandial BG and their corresponding A1C levels based on the results of this study .", "label": "", "metadata": {}, "score": "93.084595"}
{"text": "However , uncertainties with regard to dose similarities between DET and GLAR remain .The attempt to compare daily doses of DET and GLAR has been complicated by different treatment algorithms where DET is dosed once or twice daily whereas GLAR is dosed only once daily .", "label": "", "metadata": {}, "score": "93.439186"}
{"text": "Luigi Meneghini Division of Endocrinology and Diabetes , University of Miami Miller School of Medicine , 1450 NW 10 Avenue , Miami , FL 33136 , USA Diabetes Technol Ther 12:S109 - 14 .", "label": "", "metadata": {}, "score": "93.54656"}
{"text": "Luigi Meneghini Division of Endocrinology and Diabetes , University of Miami Miller School of Medicine , 1450 NW 10 Avenue , Miami , FL 33136 , USA Diabetes Technol Ther 12:S109 - 14 .", "label": "", "metadata": {}, "score": "93.54656"}
{"text": "Saydah SH , Fradkin J , Cowie CC : Poor control of risk factors for vascular disease among adults with previously diagnosed dia- betes .JAMA 2004 , 291:335 - 342 .", "label": "", "metadata": {}, "score": "93.83457"}
{"text": "Some studies have concluded that the daily DET dose is on average higher than the daily GLAR dose [ 12 ] ; [ 15 ] whereas others find no significant differences [ 14 ] .", "label": "", "metadata": {}, "score": "93.91701"}
{"text": "Furthermore , 43 patient cases were excluded because of missing body weight data .In total , 536 patient cases were included in the analyses .", "label": "", "metadata": {}, "score": "93.95798"}
{"text": "However , this study being observational and retrospective by design has several limitations .First , the two groups differ significantly at baseline in terms of age , BMI , known duration of diabetes and diabetes control .", "label": "", "metadata": {}, "score": "94.46434"}
{"text": "However , this study being observational and retrospective by design has several limitations .First , the two groups differ significantly at baseline in terms of age , BMI , known duration of diabetes and diabetes control .", "label": "", "metadata": {}, "score": "94.46434"}
{"text": "Basal insulin suppresses glucose production by the liver ( gluconeogenesis ) between meals and overnight [ 13,15,16].Prandial ( bolus ) insulin covers increases in blood glucose levels following meals [ 13].", "label": "", "metadata": {}, "score": "94.54938"}
{"text": "[Medline ] [CrossRef ] 18 .Zhang J , Tokui Y , Yamagata K , Kozawa J , Sayama K , Iwahashi H , et al .", "label": "", "metadata": {}, "score": "94.737976"}
{"text": "Results .Bivariate analysis .There was no significant difference in the mean daily doses of DET and GLAR ( see Table 1 ) .Background characteristics of the study population are shown in Table 2 .", "label": "", "metadata": {}, "score": "94.986565"}
{"text": "Luigi Meneghini Division of Endocrinology , Diabetes , and Metabolism , University of Miami Miller School of Medicine , Miami , Florida , USA Endocr Pract 17:727 - 36 .", "label": "", "metadata": {}, "score": "95.128456"}
{"text": "Baseline characteristics .At baseline , the patients of the active group were younger compared to the control group and this difference reached statistical significance .", "label": "", "metadata": {}, "score": "95.17882"}
{"text": "Baseline characteristics .At baseline , the patients of the active group were younger compared to the control group and this difference reached statistical significance .", "label": "", "metadata": {}, "score": "95.17882"}
{"text": "Metabolic Pulse Web site .Khaw KT , Wareham N , Luben R , Bingham S , Oakes S , Welch A , Day N : Glycated haemoglobin , diabetes , and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition ( EPIC - Norfolk ) .", "label": "", "metadata": {}, "score": "95.325226"}
{"text": "Medline ] [ CrossRef ] Vol.22 / No.1 .Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .", "label": "", "metadata": {}, "score": "95.366"}
{"text": "Metformin acts mainly on the liver , and suppresses hepatic glucose production by decreasing gluconeogenesis , and also increases insulin - stimulated glucose uptake in peripheral muscle and fat .", "label": "", "metadata": {}, "score": "95.729385"}
{"text": "Acknowledgements The author gratefully acknowledges Katie Singh , PharmD , of Embryon who assisted in the preparation of a first draft of this article based on an author- approved outline and assisted in implementing author revisions .", "label": "", "metadata": {}, "score": "96.40208"}
{"text": "Luigi Fernando Meneghini Diabetes Research Institute , University of Miami Miller School of Medicine , Miami , FL , USA Cell Biochem Biophys 48:97 - 102 .", "label": "", "metadata": {}, "score": "96.48885"}
{"text": "View Article .Meigs JB , Nathan DM , D'Agostino RB , Wilson PW , Framingham Offspring Study : Fasting and postchallenge glycemia and cardiovascular risk : the Framingham offspring study .", "label": "", "metadata": {}, "score": "96.53027"}
{"text": "View Article .Meigs JB , Nathan DM , D'Agostino RB , Wilson PW , Framingham Offspring Study : Fasting and postchallenge glycemia and cardiovascular risk : the Framingham offspring study .", "label": "", "metadata": {}, "score": "96.53027"}
{"text": "Position statement of the American Diabetes Association ( ADA ) and the European Association for the Study of Diabetes ( EASD ) .Diabetes Care 2012;35:1364 - 79 .", "label": "", "metadata": {}, "score": "96.57229"}
{"text": "Primary efficacy analysis .For the primary efficacy analysis , ANCOVA was used to compare change from baseline in A1C at week 24 after adjustment for baseline A1C. Secondary efficacy analyses .", "label": "", "metadata": {}, "score": "96.9019"}
{"text": "The study complied with the International Council on Harmonization E6 guideline of May 1996 and with the ethical principles of the Declaration of Helsinki .Institutional review boards approved the protocol and study documents .", "label": "", "metadata": {}, "score": "96.91075"}
{"text": "Patient cases with missing values were excluded from the analyses .All statistical tests were performed at 5 % significance level .Ethics .Approval from an ethics committee was not required by Danish law since the study did not involve collection of or research on biological material .", "label": "", "metadata": {}, "score": "97.09315"}
{"text": "10.1046/j.1463 - 1326.2003.00277.x .View Article PubMed .Clin Ther .10.1016/j.clinthera.2007.11.016 .View Article PubMed .Diabet Med .2012 , 29 : e263-e272 .", "label": "", "metadata": {}, "score": "97.155304"}
{"text": "For example , on odd - numbered days of the month , premeal glucose levels should be tested before breakfast and lunch .On even - numbered days of the month , premeal glucose levels should be tested before dinner and at bedtime .", "label": "", "metadata": {}, "score": "97.64375"}
{"text": "Khaw KT , Wareham N , Bingham S , Luben R , Welch A , Day N : Asso- ciation of hemoglobin AIC with cardiovascular disease and mortality in adults : the European Prospective Investigation into Cancer in Norfolk .", "label": "", "metadata": {}, "score": "98.084045"}
{"text": "Premixed analogues provide both basal and postprandial coverage starting with 1 injection , but they are generally administered twice daily ( BID ) , 1 injection at breakfast and 1 at supper .", "label": "", "metadata": {}, "score": "98.277245"}
{"text": "When glycemic control is achieved , measurements of BG can be performed less frequently ( preferably before breakfast , 1 - 2 times a week ) to confirm that adequate glycemic control is being maintained .", "label": "", "metadata": {}, "score": "98.337814"}
{"text": "10.1111/j.1464 - 5491.2009.02824.x .View Article PubMed .AACE / ACE Consenus Statement : Statement by an American Association of Clinical Endocrinologists / American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus : An Algorithm for Glycemic Control .", "label": "", "metadata": {}, "score": "98.435585"}
{"text": "Lancet .American Diabetes Association : Standards of medical care in diabetes-2012 .Diabetes Care .2012 , 35 ( Suppl 1 ) : S11-S63 .", "label": "", "metadata": {}, "score": "98.53138"}
{"text": "OADs were also added or withdrawn on the basis of the attending physician 's global assessment of the efficacy of treatment schemes and the changes were reported on the patients ' case records .", "label": "", "metadata": {}, "score": "98.85132"}
{"text": "OADs were also added or withdrawn on the basis of the attending physician 's global assessment of the efficacy of treatment schemes and the changes were reported on the patients ' case records .", "label": "", "metadata": {}, "score": "98.85132"}
{"text": "The statistical significance of body weight changes in each treatment group was evaluated by one - way analysis of variance ( ANOVA ) tests .All statistical tests were two - tailed and the significance level was set to 5 % .", "label": "", "metadata": {}, "score": "98.96098"}
{"text": "The statistical significance of body weight changes in each treatment group was evaluated by one - way analysis of variance ( ANOVA ) tests .All statistical tests were two - tailed and the significance level was set to 5 % .", "label": "", "metadata": {}, "score": "98.96098"}
{"text": "LADA is caused by immune - mediated destruc- tion of the insulin - producing pancreatic p - cells , similar to type 1 diabetes but typically is diagnosed in patients aged 30 - 40 years ( the diagnosis is confirmed by blood tests for the presence of glutamic acid decarboxylase antibodies ) [ 25,26].", "label": "", "metadata": {}, "score": "99.08809"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations . 1stDepartment of Propaedeutic and Internal Medicine , Athens University Medical School , Laiko General Hospital .", "label": "", "metadata": {}, "score": "99.1487"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations . 1stDepartment of Propaedeutic and Internal Medicine , Athens University Medical School , Laiko General Hospital .", "label": "", "metadata": {}, "score": "99.1487"}
{"text": "Efficacy .The primary end point was the change in A1C from baseline to week 24 .Safety .All adverse events were recorded .Clinical chemistry and hematology values and physical examination results , including weight and vital signs , were documented .", "label": "", "metadata": {}, "score": "99.29167"}
{"text": "A Poisson regression model , incorporating overdispersion , was used to analyze the rate of hypoglycemia , and a logistic regression model was used to analyze incidence of hypoglycemia .", "label": "", "metadata": {}, "score": "99.5013"}
{"text": "Position statement of the American Diabetes Association ( ADA ) and the European Association for the Study of Diabetes ( EASD ) .Diabetologia .10.1007/s00125 - 012 - 2534 - 0 .", "label": "", "metadata": {}, "score": "99.59706"}
{"text": "PubMed Central View Article PubMed .Nathan DM , Singer DE , Hurxthal K , Goodson JD : The clinical information value of the glycosylated hemoglobin assay .", "label": "", "metadata": {}, "score": "99.59912"}
{"text": "The JSPE surveyed 259 children with T2DM , all less than 18 yr , of age and treated at 42 medical centers in 2003 , and examined how antidiabetic drugs were used at the time of diagnosis and survey .", "label": "", "metadata": {}, "score": "99.76907"}
{"text": "Among these 49 patients , 26 were obese and 23 nonobese .Overall frequencies of progression to pharmacologic therapies in the obese and nonobese patients were 32.5 % and 82.1 % , respectively .", "label": "", "metadata": {}, "score": "100.461395"}
{"text": "RESEARCH DESIGN AND METHODS- .This multicenter , controlled , open , randomized , parallel - group study included 2 weeks of screening followed by 24 weeks of treatment .", "label": "", "metadata": {}, "score": "100.4652"}
{"text": "Analyses were performed using the statistical package SAS 9.2 for Windows ( SAS Institute , Cary , NC , USA ) .Both bivariate analyses and multivariate linear regression analyses were applied to examine possible differences in the daily doses of DET and GLAR .", "label": "", "metadata": {}, "score": "101.04054"}
{"text": "We used percent overweight as an index of obesity in this study .The percent overweight was calculated as ( current weight - sex- , age- and height - matched ideal weight ) / sex- , age- and height - matched ideal weight \u00d7 100 ( % ) .", "label": "", "metadata": {}, "score": "101.17757"}
{"text": "Patients treated with metformin are monitored in order to detect increasing levels of creatinine .Typical contraindications for metformin use are kidney , heart , liver , and lung failure .", "label": "", "metadata": {}, "score": "101.41687"}
{"text": "It is important to note that patients can achieve lower postprandial BG concentrations by reducing high glycemic index carbohydrates ( potatoes , white rice , white bread , white flour , white pasta , polenta , etc . ) in their diets [ 49 ] .", "label": "", "metadata": {}, "score": "101.55989"}
{"text": "Glycemic control is important for the prevention of diabetes - related complications in T2D patients , e.g. heart disease , stroke , high blood pressure , blindness , kidney disease , neuropathy and amputations [ 3 ] .", "label": "", "metadata": {}, "score": "101.65602"}
{"text": "Approximately 12.4 million adults ( 20 - 79 years of age ) in Brazil had diabetes in 2011 ; this is expected to increase to 19.6 million by 2030 [ 1 ] .", "label": "", "metadata": {}, "score": "102.17061"}
{"text": "L F Meneghini University of Miami Miller School of Medicine , 1450 NW 10th Avenue , Miami , FL 33136 , USA Curr Med Res Opin 25:1029 - 35 .", "label": "", "metadata": {}, "score": "102.66359"}
{"text": "Frequency and mean values were compared using the \u03c72 test or Mann - Whitney U - test to detect differences between the data , respectively .", "label": "", "metadata": {}, "score": "102.83679"}
{"text": "Two - sample Wilcoxon tests or Pearson 's \u03c7 2 tests were used to compare patient demographic and clinical characteristics as well as outcomes measures between treatment groups .", "label": "", "metadata": {}, "score": "103.12341"}
{"text": "Medline ] [ CrossRef ] 14 .Del Guerra S , Grupillo M , Masini M , Lupi R , Bugliani M , Torri S , et al .", "label": "", "metadata": {}, "score": "103.15566"}
{"text": "As illustrated in Figure 1 , the participating GP offices and specialists returned 640 questionnaires and 299 questionnaires , respectively , providing data on 939 patient cases in total .", "label": "", "metadata": {}, "score": "103.224846"}
{"text": "Diabetic ketoacidosis ( DKA ) is the most serious hyperglycemic emergency in patients with type 1 and type 2 diabetes .It has been estimated that treatment of DKA episodes represent more than one of every four health care dollars spent on direct medical care for adult patients with type 1 diabetes ( 4 ) .", "label": "", "metadata": {}, "score": "103.459656"}
{"text": "Severe life - threatening , generalized allergy , including anaphylaxis , can occur .Discontinue Lantus \u00ae , treat and monitor until symptoms resolve .A reduction in the Lantus \u00ae dose may be required in patients with renal or hepatic impairment .", "label": "", "metadata": {}, "score": "103.5057"}
{"text": "Severe life - threatening , generalized allergy , including anaphylaxis , can occur .Discontinue Lantus \u00ae , treat and monitor until symptoms resolve .A reduction in the Lantus \u00ae dose may be required in patients with renal or hepatic impairment .", "label": "", "metadata": {}, "score": "103.5057"}
{"text": "Severe life - threatening , generalized allergy , including anaphylaxis , can occur .Discontinue Lantus \u00ae , treat and monitor until symptoms resolve .A reduction in the Lantus \u00ae dose may be required in patients with renal or hepatic impairment .", "label": "", "metadata": {}, "score": "103.5057"}
{"text": "Severe life - threatening , generalized allergy , including anaphylaxis , can occur .Discontinue Lantus \u00ae , treat and monitor until symptoms resolve .A reduction in the Lantus \u00ae dose may be required in patients with renal or hepatic impairment .", "label": "", "metadata": {}, "score": "103.5057"}
{"text": "Fasting BG declined significantly in both treatment groups during the monitoring period .Hypoglycaemic episodes .The monthly number of mild / moderate hypoglycaemic episodes , the nocturnal episodes , and the serious hypoglycaemic episodes did not differ significantly between the treatment groups during the monitoring period ( Tables 4 and 5 ) .", "label": "", "metadata": {}, "score": "103.56234"}
{"text": "Fasting BG declined significantly in both treatment groups during the monitoring period .Hypoglycaemic episodes .The monthly number of mild / moderate hypoglycaemic episodes , the nocturnal episodes , and the serious hypoglycaemic episodes did not differ significantly between the treatment groups during the monitoring period ( Tables 4 and 5 ) .", "label": "", "metadata": {}, "score": "103.56234"}
{"text": "Voiceover : The effect of these changes is to shift the isoelectric point , producing a solution that is completely soluble at pH 4 .Frame 5 .", "label": "", "metadata": {}, "score": "103.7073"}
{"text": "The LS mean ( 95 % CI ) reduction of HbA1c value was -1.13 ( -0.96 to -1.30)% ] in the active and-0.59( -0.41 to -0.77)% ] in the control group .", "label": "", "metadata": {}, "score": "103.717995"}
{"text": "The LS mean ( 95 % CI ) reduction of HbA1c value was -1.13 ( -0.96 to -1.30)% ] in the active and-0.59( -0.41 to -0.77)% ] in the control group .", "label": "", "metadata": {}, "score": "103.717995"}
{"text": "MT , MN , and JG do not have any financial competing interests in relation to the manuscript .ME is a former Lilly employee , and CO is a Lilly employee and as such , own Lilly stock .", "label": "", "metadata": {}, "score": "105.18239"}
{"text": "Luigi F Meneghini University of Miami Miller School of Medicine , 1450 NW 10th Ave , Miami , FL 33136 , USA Endocrine 43:529 - 34 .", "label": "", "metadata": {}, "score": "105.540405"}
{"text": "Adjusted mean total cholesterol decreased slightly in both groups from baseline to week 24 .Neither HDL nor LDL cholesterol changed significantly from baseline to week 24 in either group ; no between - group differences were observed at week 12 or 24 .", "label": "", "metadata": {}, "score": "105.72835"}
{"text": "Of 281 patients randomized , 273 comprised the ITT population ( Table 2 ) ( 136 simple algorithm and 137 carb count ) ( Fig . 1 ) .", "label": "", "metadata": {}, "score": "106.435936"}
{"text": "Luigi F Meneghini University of Miami Miller School of Medicine , Miami , Fla 33157 , USA Am J Med 126:S28 - 37 .", "label": "", "metadata": {}, "score": "106.508316"}
{"text": "Luigi F Meneghini University of Miami Miller School of Medicine , Miami , Fla 33157 , USA Am J Med 126:S28 - 37 .", "label": "", "metadata": {}, "score": "106.508316"}
{"text": "Authors ' contributions .The authors ( MT , MN , JG , ME , and CO ) have made substantive intellectual contributions to a published study and participated sufficiently in the work to take public responsibility for appropriate portions of the content .", "label": "", "metadata": {}, "score": "107.76677"}
{"text": "Severe hypoglycaemia was defined as any hypoglycaemic episode that the patient was unable to self - treat requiring the assistance of another person to deal with it [ 5 ] .", "label": "", "metadata": {}, "score": "108.52104"}
{"text": "Severe hypoglycaemia was defined as any hypoglycaemic episode that the patient was unable to self - treat requiring the assistance of another person to deal with it [ 5 ] .", "label": "", "metadata": {}, "score": "108.52104"}
{"text": "Changes in HBA1c and fasting blood glucose levels .A The reduction in HbA1c levels in the control ( grey bars ) and the active group ( black bar ) after 6 - 12 months of follow up .", "label": "", "metadata": {}, "score": "108.5847"}
{"text": "Changes in HBA1c and fasting blood glucose levels .A The reduction in HbA1c levels in the control ( grey bars ) and the active group ( black bar ) after 6 - 12 months of follow up .", "label": "", "metadata": {}, "score": "108.5847"}
{"text": "Statistical analysis .Data were analyzed separately in each treatment group ( control / active group ) .Continuous variables were presented by measures of central tendency and dispersion , whereas categorical variables by frequency distribution tables .", "label": "", "metadata": {}, "score": "109.39964"}
{"text": "Statistical analysis .Data were analyzed separately in each treatment group ( control / active group ) .Continuous variables were presented by measures of central tendency and dispersion , whereas categorical variables by frequency distribution tables .", "label": "", "metadata": {}, "score": "109.39964"}
{"text": "10.2337/diacare.28.2.254 .View Article PubMed .Workgroup on Hypoglycemia , American Diabetes Association : Defining and reporting hypoglycemia in diabetes : a report from the American Diabetes Association Workgroup on Hypoglycemia .", "label": "", "metadata": {}, "score": "109.551186"}
{"text": "10.2337/diacare.28.2.254 .View Article PubMed .Workgroup on Hypoglycemia , American Diabetes Association : Defining and reporting hypoglycemia in diabetes : a report from the American Diabetes Association Workgroup on Hypoglycemia .", "label": "", "metadata": {}, "score": "109.551186"}
{"text": "Adverse reactions commonly associated with Lantus \u00ae include hypoglycemia , allergic reactions , injection site reactions , lipodystrophy , pruritus , rash , edema and weight gain .", "label": "", "metadata": {}, "score": "109.70654"}
{"text": "Adverse reactions commonly associated with Lantus \u00ae include hypoglycemia , allergic reactions , injection site reactions , lipodystrophy , pruritus , rash , edema and weight gain .", "label": "", "metadata": {}, "score": "109.70654"}
{"text": "Adverse reactions commonly associated with Lantus \u00ae include hypoglycemia , allergic reactions , injection site reactions , lipodystrophy , pruritus , rash , edema and weight gain .", "label": "", "metadata": {}, "score": "109.70654"}
{"text": "Adverse reactions commonly associated with Lantus \u00ae include hypoglycemia , allergic reactions , injection site reactions , lipodystrophy , pruritus , rash , edema and weight gain .", "label": "", "metadata": {}, "score": "109.70654"}
{"text": "Untreated hypokalemia may cause respiratory paralysis , ventricular arrhythmia , and death .Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated .", "label": "", "metadata": {}, "score": "110.04352"}
{"text": "Untreated hypokalemia may cause respiratory paralysis , ventricular arrhythmia , and death .Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated .", "label": "", "metadata": {}, "score": "110.04352"}
{"text": "Untreated hypokalemia may cause respiratory paralysis , ventricular arrhythmia , and death .Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated .", "label": "", "metadata": {}, "score": "110.04352"}
{"text": "Untreated hypokalemia may cause respiratory paralysis , ventricular arrhythmia , and death .Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated .", "label": "", "metadata": {}, "score": "110.04352"}
{"text": "U : . unit .Kg : . kilo .Cm : . centimetre .M : . metre .Declarations .Acknowledgements .We acknowledge The Nielsen Company for collecting the data from GPs and specialists used in this study .", "label": "", "metadata": {}, "score": "111.16757"}
{"text": "Second , the number of mild / moderate hypoglycaemic episodes might have been under - reported in medical records and therefore , underestimated .Third , detailed data for documented symptomatic hypoglycaemia , asymptomatic hypoglycaemia , probable symptomatic hypoglycaemia and relative hypoglycaemia were not available and all cases of hypoglycaemia other than severe hypoglycaemia were classified as mild or moderate hypoglycaemia .", "label": "", "metadata": {}, "score": "111.29445"}
{"text": "Second , the number of mild / moderate hypoglycaemic episodes might have been under - reported in medical records and therefore , underestimated .Third , detailed data for documented symptomatic hypoglycaemia , asymptomatic hypoglycaemia , probable symptomatic hypoglycaemia and relative hypoglycaemia were not available and all cases of hypoglycaemia other than severe hypoglycaemia were classified as mild or moderate hypoglycaemia .", "label": "", "metadata": {}, "score": "111.29445"}
{"text": "Authors ' contributions .NT was principal investigator , study co - ordinator and investigator , participated in all stages of recruitment of the patients and in analysis of the data , drafted and reviewed critically the manuscript .", "label": "", "metadata": {}, "score": "111.35878"}
{"text": "Authors ' contributions .NT was principal investigator , study co - ordinator and investigator , participated in all stages of recruitment of the patients and in analysis of the data , drafted and reviewed critically the manuscript .", "label": "", "metadata": {}, "score": "111.35878"}
{"text": "Voiceover : When micro precipitates develop , the hexamer is subdivided into three dimers , each of which divides into two monomers .Frame 8 .", "label": "", "metadata": {}, "score": "112.01631"}
{"text": "Conclusions .Authors ' information .Study investigators .Declarations .Acknowledgments .The study and the editorial support were funded by sanofi - aventis , Greece .", "label": "", "metadata": {}, "score": "112.51065"}
{"text": "Conclusions .Authors ' information .Study investigators .Declarations .Acknowledgments .The study and the editorial support were funded by sanofi - aventis , Greece .", "label": "", "metadata": {}, "score": "112.51065"}
{"text": "A1C is a function of FBG and postprandial BG , but the percentages and conditions under which each of these components contributes to A1C values have remained largely unknown .", "label": "", "metadata": {}, "score": "112.53598"}
{"text": "The diagnosis of DKA was established by standard criteria ( 8 ) .This study was conducted at Grady Memorial Hospital , Atlanta , Georgia , and at Hennepin County Medical Center , Minneapolis , Minnesota , and was approved by dual institutional review boards .", "label": "", "metadata": {}, "score": "113.70954"}
{"text": "PubMed View Article .Pre - publication history .Copyright .\u00a9 Jakobsen et al . ; licensee BioMed Central Ltd. 2012 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "113.90994"}
{"text": "Safety .Adverse events .The population used to determine adverse events and hypoglycemia came from the safety population .Of 42 serious adverse events , 41 were nonfatal : 22 ( 15.9 % ) in the simple algorithm group and 19 ( 13.7 % ) in the carb count group .", "label": "", "metadata": {}, "score": "115.45064"}
{"text": "Footnotes .The sponsors of the study were not involved in the study design , data collection , analysis interpretation of the results , or preparation of the manuscript .", "label": "", "metadata": {}, "score": "115.66038"}
{"text": "Including CV death , nonfatal MI , nonfatal stroke , revascularization , or hospitalization for heart failure .No difference was observed between Lantus \u00ae and standard of care in overall incidence of CV death , nonfatal MI , or nonfatal stroke .", "label": "", "metadata": {}, "score": "117.44538"}
{"text": "Diaries .Visits .Study visits occurred at screening , at baseline , and at weeks 2 , 6 , 12 , 18 , and 24 ( end point ) .", "label": "", "metadata": {}, "score": "117.94996"}
{"text": "Declarations .Acknowledgements .The authors would like to acknowledge the medical writing assistance provided by Keyra Martinez Dunn , MD of PRIMO Scientific Corporation , Panama , Republic of Panama .", "label": "", "metadata": {}, "score": "118.06406"}
{"text": "B : FPG : change from baseline in simple algorithm and carb count groups at weeks 2 , 6 , 12 , 18 , and 24 ( ITT population ) .", "label": "", "metadata": {}, "score": "118.186966"}
{"text": "10.1007/s00125 - 009 - 1468 - 7 .View Article PubMed .Copyright .\u00a9 Tentolouris et al . ; licensee BioMed Central Ltd. 2013 .", "label": "", "metadata": {}, "score": "119.58058"}
{"text": "10.1007/s00125 - 009 - 1468 - 7 .View Article PubMed .Copyright .\u00a9 Tentolouris et al . ; licensee BioMed Central Ltd. 2013 .", "label": "", "metadata": {}, "score": "119.58058"}
{"text": "PubMed Central View Article PubMed .N Engl J Med .10.1056/NEJMoa0808431 .View Article PubMed .N Engl J Med .View Article PubMed .", "label": "", "metadata": {}, "score": "121.704796"}
{"text": "Voiceover : The amino acid asparagine at the position A21 is replaced by glycine and two arginines are added to the C terminus of the B chain .", "label": "", "metadata": {}, "score": "123.74995"}
{"text": "Competing interests Steven Edelman , MD , George Dailey , MD , Thomas Flood , MD , and Susan Renda , CRNP , CDE , declare they have no competing interests .", "label": "", "metadata": {}, "score": "133.18167"}
{"text": "Publisher conditions are provided by RoMEO .Differing provisions from the publisher 's actual policy or licence agreement may be applicable .", "label": "", "metadata": {}, "score": "135.49359"}
